<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Septic shock in children in resource-abundant settings: Rapid recognition and initial resuscitation (first hour)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Septic shock in children in resource-abundant settings: Rapid recognition and initial resuscitation (first hour)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Septic shock in children in resource-abundant settings: Rapid recognition and initial resuscitation (first hour)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Scott L Weiss, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Wendy J Pomerantz, MD, MS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Adrienne G Randolph, MD, MSc</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Torrey, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheldon L Kaplan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James F Wiley, II, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 10, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H19451388"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The early recognition and initial management of severe sepsis and septic shock in children in resource-abundant settings during the critical first hour of resuscitation are reviewed here.</p><p>The definitions, epidemiology, and clinical manifestations of sepsis in children, ongoing management of children with septic shock, and the evaluation and management of neonatal shock in resource-abundant settings and the recognition and initial management of shock in children in resource-limited settings are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6395.html" rel="external">"Sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/86881.html" rel="external">"Septic shock in children in resource-abundant settings: Ongoing management after resuscitation"</a>.)\</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5039.html" rel="external">"Neonatal shock: Etiology, clinical manifestations, and evaluation"</a> and  <a class="medical medical_review" href="/d/html/126605.html" rel="external">"Neonatal shock: Management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/143443.html" rel="external">"Shock in children in resource-limited settings: Recognition"</a> and  <a class="medical medical_review" href="/d/html/138933.html" rel="external">"Shock in children in resource-limited settings: Initial management"</a>.)</p><p></p><p class="headingAnchor" id="H25706214"><span class="h1">DEFINITIONS</span><span class="headingEndMark"> — </span>In 2005, the International Pediatric Consensus Conference defined sepsis in children as two or more of the criteria for the systemic inflammatory response syndrome (SIRS)  (<a class="graphic graphic_table graphicRef86087" href="/d/graphic/86087.html" rel="external">table 1</a>) due to a suspected or proven infection. (See  <a class="medical medical_review" href="/d/html/6395.html" rel="external">"Sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis", section on 'Sepsis'</a>.)</p><p>Severe sepsis was defined as all of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>≥2 age-based SIRS criteria</p><p class="bulletIndent1"><span class="glyph">●</span>Suspected or proven invasive infection</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiovascular dysfunction, acute respiratory distress syndrome (ARDS), or ≥2 noncardiovascular organ system dysfunctions</p><p></p><p>Septic shock was defined as the subset with cardiovascular dysfunction, which includes at least one of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypotension</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reliance on vasoactive drug administration to maintain a normal blood pressure</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two or more of the following signs of inadequate tissue perfusion:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prolonged capillary refill</p><p class="bulletIndent2"><span class="glyph">•</span>Oliguria</p><p class="bulletIndent2"><span class="glyph">•</span>Metabolic acidosis</p><p class="bulletIndent2"><span class="glyph">•</span>Elevated blood lactate</p><p></p><p>Although these specific definitions are useful, sepsis presents as a clinical syndrome complicating severe infection that is characterized by multiple heterogeneous features including systemic inflammation, immune dysregulation, microcirculatory derangements, and end-organ dysfunction. The severity of illness for an individual patient is a continuum through which it may be clinically impossible to distinguish transitions from sepsis to severe sepsis and septic shock.</p><p class="headingAnchor" id="H2112244167"><span class="h1">APPROACH</span><span class="headingEndMark"> — </span>Our approach is consistent with the 2020 Surviving Sepsis Campaign International Guidelines for the management of septic shock and sepsis-associated organ dysfunction in children [<a href="#rid1">1,2</a>]. Specific management steps for facilities with access to intensive care are provided in the algorithm  (<a class="graphic graphic_algorithm graphicRef128375" href="/d/graphic/128375.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H19451395"><span class="h1">RAPID RECOGNITION</span><span class="headingEndMark"> — </span>The goal of the initial phase of management for children with septic shock is to rapidly recognize those with infections who have severe sepsis (and are at risk for rapid progression to septic shock) as well as those with septic shock.</p><p>Septic shock is associated with high morbidity and mortality. In addition, delayed recognition of septic shock has repeatedly been associated with worse clinical outcomes in adults and children [<a href="#rid3">3</a>]. As an example, in a prospective cohort study of 91 infants and children presenting to community hospitals with septic shock (defined by hypotension or delayed capillary refill), each hour of delay in initiation of appropriate resuscitation or persistence of hemodynamic abnormalities was associated with a clinically significant increased risk of death (odds ratio [OR] 1.5 and 2.3, respectively) [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/d/html/6395.html" rel="external">"Sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis", section on 'Definitions'</a> and  <a class="medical medical_review" href="/d/html/6395.html" rel="external">"Sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis", section on 'Sepsis'</a>.)</p><p class="headingAnchor" id="H2139986422"><span class="h2">Institutional approach</span><span class="headingEndMark"> — </span>To minimize delays in recognition of severe sepsis and septic shock, each pediatric institution should develop a multidisciplinary protocol/guideline to improve early identification and treatment. The major components of the recognition bundle that are recommended by the pediatric 2020 Surviving Sepsis Campaign International Guidelines include [<a href="#rid1">1,2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systematic screening for</strong> <strong>identification of severe sepsis or septic shock</strong> – Institutions should implement a septic shock identification/trigger tool that consists of combinations of clinical diagnoses and findings (eg, high-risk patient conditions, vital signs, and/or physical findings) that prompt further evaluation.</p><p></p><p class="bulletIndent1">The tool should be adapted to the setting and patient population where it will be used. Implementation through an electronic health record may facilitate clinician compliance. An example of an emergency department trigger tool designed for use by triage nurses and incorporating vital sign thresholds used in the Pediatric Advanced Life Support course is provided  (<a class="graphic graphic_algorithm graphicRef113645" href="/d/graphic/113645.html" rel="external">algorithm 2</a>). Some institutions may choose previously proposed vital sign triggers  (<a class="graphic graphic_table graphicRef86087" href="/d/graphic/86087.html" rel="external">table 1</a>). Each institution should base their vital sign triggers on their best interpretation of the evidence and what will be most functional in their system.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rapid clinical assessment for patients with possible severe sepsis/septic shock</strong> – Once screening with the trigger tool indicates that a patient may have severe sepsis/septic shock, they should undergo rapid clinical assessment within 15 minutes by a physician, physician assistant, or advanced practice nurse to confirm findings of septic shock, implement additional monitoring, and determine the resuscitation plan.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rapid initiation of resuscitation</strong> – Resuscitation should be initiated within 15 minutes of confirming severe sepsis or septic shock. (See <a class="local">'Resuscitation'</a> below.)</p><p></p><p class="headingAnchor" id="H3669730948"><span class="h2">Red-flag findings</span><span class="headingEndMark"> — </span>Red-flag findings that should prompt rapid clinical assessment and resuscitation for severe sepsis or septic shock include [<a href="#rid5">5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Presence of fever (core temperature &gt;38.3°C [101°F] for patients three months of age and older or &gt;38°C [100.4°F] for infants younger than three months of age)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypothermia (core temperature &lt;36°C [96.8°F])</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tachycardia</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tachypnea</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal pulse (diminished, weak, or bounding)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal capillary refill (central refill ≥3 seconds or flash refill [&lt;1 second])</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypotensive</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal mental status:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Irritability</p><p class="bulletIndent2"><span class="glyph">•</span>Inappropriate crying</p><p class="bulletIndent2"><span class="glyph">•</span>Inappropriate drowsiness (eg, excessive per caregiver)</p><p class="bulletIndent2"><span class="glyph">•</span>Not interacting with caregiver</p><p class="bulletIndent2"><span class="glyph">•</span>Difficult to arouse (lethargic or obtunded)</p><p class="bulletIndent2"><span class="glyph">•</span>Confused (not oriented to person, place, or time when developmentally appropriate to test)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Purpura anywhere on the body or petechiae below the nipple line  (<a class="graphic graphic_picture graphicRef74453" href="/d/graphic/74453.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef73905" href="/d/graphic/73905.html" rel="external">picture 2</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Macular erythema  (<a class="graphic graphic_picture graphicRef61786" href="/d/graphic/61786.html" rel="external">picture 3</a> and <a class="graphic graphic_picture graphicRef82561" href="/d/graphic/82561.html" rel="external">picture 4</a>) with mucosal changes (eg, strawberry tongue and conjunctival injection  (<a class="graphic graphic_picture graphicRef66457" href="/d/graphic/66457.html" rel="external">picture 5</a>)) suggestive of toxic shock syndrome</p><p></p><p>Tachycardia and tachypnea are common and nonspecific findings in young pediatric patients and may be due to fever, anxiety, dehydration, pain/discomfort, anemia, or agitation. In febrile children, the heart rate may be adjusted by deducting approximately 10 beats per minute for every 1°C (1.8°F) elevation in temperature. However, tachycardia should resolve when the temperature returns to normal; persistent sinus tachycardia is a sensitive indicator of circulatory dysfunction and should <strong>not</strong> be overlooked. (See  <a class="medical medical_review" href="/d/html/6435.html" rel="external">"Approach to the child with tachycardia", section on 'Vital signs'</a>.)</p><p>Clinicians must appreciate that hypotension is a late sign of cardiovascular dysfunction and shock in pediatric patients and is <strong>not</strong> necessary to diagnose septic shock. Infants and children with sepsis often maintain blood pressure despite the presence of septic shock through an increase in heart rate, systemic vascular resistance, and venous tone but have a limited capacity to augment myocardial stroke volume. As a result, infants and children may be more likely to exhibit "cold" shock in sepsis compared with the classic presentation of "warm" (or hyperdynamic/vasodilated) shock in adults. (See  <a class="medical medical_review" href="/d/html/6395.html" rel="external">"Sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis", section on 'Shock'</a>.)</p><p>Rapid resuscitation that is tailored to the patient's clinical condition and to the presence or absence of intensive care services should be started in patients with red-flag findings for sepsis or septic shock. (See <a class="local">'Resuscitation'</a> below.)</p><p class="headingAnchor" id="H2027369626"><span class="h2">Signs and symptoms of infection</span><span class="headingEndMark"> — </span>In addition to the red-flag findings listed above, signs and symptoms of infection support the clinical suspicion of septic shock. Common clinical findings found in children with sepsis and septic shock include:</p><p class="bulletIndent1"><span class="glyph">●</span>Toxic or ill appearance</p><p class="bulletIndent1"><span class="glyph">●</span>Signs of dehydration  (<a class="graphic graphic_table graphicRef76198" href="/d/graphic/76198.html" rel="external">table 2</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Rigors</p><p class="bulletIndent1"><span class="glyph">●</span>Decreased tone in neonates and infants</p><p class="bulletIndent1"><span class="glyph">●</span>Seizures</p><p class="bulletIndent1"><span class="glyph">●</span>Meningismus</p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory depression or failure</p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary rales or decreased breath sounds caused by bronchopneumonia</p><p class="bulletIndent1"><span class="glyph">●</span>Distended, tender abdomen (eg, perforated viscus or intraabdominal abscess)</p><p class="bulletIndent1"><span class="glyph">●</span>Costovertebral angle tenderness (eg, pyelonephritis)</p><p class="bulletIndent1"><span class="glyph">●</span>Macular erythema (toxic shock syndrome)</p><p class="bulletIndent1"><span class="glyph">●</span>Skin cellulitis, lymphangitis, or abscess  (<a class="graphic graphic_picture graphicRef53261" href="/d/graphic/53261.html" rel="external">picture 6</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Warmth, swelling, and/or erythema of an extremity or joint suggestive of osteomyelitis and/or septic arthritis</p><p class="bulletIndent1"><span class="glyph">●</span>Peripheral edema caused by capillary leak</p><p class="bulletIndent1"><span class="glyph">●</span>Multiple nodules that can be seen with disseminated <em>Staphylococcus aureus</em> or fungal infections  (<a class="graphic graphic_picture graphicRef86621" href="/d/graphic/86621.html" rel="external">picture 7</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Ecthyma associated with <em>Pseudomonas</em> infection  (<a class="graphic graphic_picture graphicRef80582" href="/d/graphic/80582.html" rel="external">picture 8</a> and <a class="graphic graphic_picture graphicRef114332" href="/d/graphic/114332.html" rel="external">picture 9</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Purpura associated with <em>Neisseria meningitidis</em> and <em>Streptococcus pneumoniae</em> as well as other bacterial etiologies</p><p></p><p class="headingAnchor" id="H19450185"><span class="h1">RESUSCITATION</span></p><p class="headingAnchor" id="H2060049524"><span class="h2">Institutional guidelines and protocols</span><span class="headingEndMark"> — </span>Each institution should develop a multidisciplinary approach to the resuscitation of pediatric patients with severe sepsis or septic shock that codifies the time-limited stabilization tasks recommended within the first few hours of treatment by the Surviving Sepsis Campaign [<a href="#rid1">1,2</a>].</p><p>Institutional implementation of resuscitation protocols and guidelines with transparent goals can improve adherence to best practices, decrease time to therapy, and improve outcomes in pediatric septic shock [<a href="#rid3">3,6,7</a>]. As an example, in an observational study that compared outcomes before and after implementation of a sepsis resuscitation protocol, time from triage to receipt of the first fluid bolus significantly decreased from a median of 56 to 22 minutes and from triage to the first antibiotic from a median of 130 to 30 minutes [<a href="#rid6">6</a>]. In another study that evaluated the impact of specific quality improvement interventions in a pediatric emergency department, adherence to timely performance of essential actions within 60 minutes of recognition quadrupled (from 19 to 78 percent) [<a href="#rid7">7</a>]. The essential actions consisted of:</p><p class="bulletIndent1"><span class="glyph">●</span>Recognition of septic shock</p><p class="bulletIndent1"><span class="glyph">●</span>Vascular access and rapid fluid resuscitation </p><p class="bulletIndent1"><span class="glyph">●</span>Empiric antimicrobial therapy</p><p class="bulletIndent1"><span class="glyph">●</span>Initiation of vasoactive agents to patients not responding sufficiently to fluid resuscitation</p><p></p><p>This improvement in guideline adherence was associated with a decrease in mortality from 5 to 2 percent.</p><p class="headingAnchor" id="H2493912177"><span class="h2">Approach</span><span class="headingEndMark"> — </span>The approach provided in this topic is largely consistent with goal-targeted therapy for pediatric septic shock recommended by the 2020 Surviving Sepsis Campaign guidance [<a href="#rid1">1,2</a>]. Goal-targeted therapy for septic shock refers to an aggressive systematic approach to resuscitation aimed at improving physiologic indicators of perfusion and vital organ function within the first few hours of care. Timing is determined by whether the child has septic shock or sepsis:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Septic shock</strong> – For children with septic shock, for whom clinical recognition of abnormal perfusion or hypotension is typically evident without the need for additional laboratory testing, the following six management steps should be accomplished within <strong>one hour</strong> of recognition  (<a class="graphic graphic_algorithm graphicRef113645" href="/d/graphic/113645.html" rel="external">algorithm 2</a> and <a class="graphic graphic_algorithm graphicRef128375" href="/d/graphic/128375.html" rel="external">algorithm 1</a>) [<a href="#rid1">1,2</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Obtain intravenous (IV)/intraosseous (IO) access.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Collect blood culture (before antibiotics are administered whenever possible).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Start broad-spectrum, empiric antimicrobial therapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Measure blood lactate (if available).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Administer a fluid bolus of 10 to 20 mL/kg if shock is present and provide further fluid resuscitation depending upon patient condition and response. (See <a class="local">'Fluid resuscitation'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Start vasoactive agents if shock persists after 40 to 60 mL/kg (or sooner if signs of fluid overload develop or myocardial dysfunction is present).</p><p></p><p class="bulletIndent1">Additional goals within the first hour are to [<a href="#rid5">5</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Maintain or restore airway, oxygenation, and ventilation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Assess cardiac function.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Reassess hemodynamic response to fluid and/or vasoactive therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sepsis</strong> – For children with suspected sepsis but without clinical evidence of shock, the same management steps are recommended if an expedited diagnostic evaluation supports the diagnosis of sepsis. Both the expedited diagnostic evaluation, which includes additional laboratory and clinical testing to assess for infection and organ dysfunction, and initiation of the above management steps should occur within <strong>three hours</strong> of initial suspicion of sepsis (but start as soon as sepsis is evident) [<a href="#rid1">1,2</a>].</p><p></p><p>Restoration of tissue perfusion and reversal of shock is identified by the following therapeutic endpoints (goals below in parentheses)</p><p>[<a href="#rid5">5,8,9</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Quality of central and peripheral pulses (strong, distal pulses equal to central pulses)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Skin perfusion (warm, with capillary refill &lt;2 seconds)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mental status (normal mental status)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urine output (≥1 mL/kg/hour, up to 40 mL/hour, once effective circulating volume is restored)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Blood pressure (systolic pressure at least fifth percentile for age):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>&lt;1 month of age: 60 mmHg</p><p class="bulletIndent2"><span class="glyph">•</span>1 month to 10 years of age: 70 mmHg + [2 x age in years] </p><p class="bulletIndent2"><span class="glyph">•</span>10 years of age and older: 90 mmHg</p><p></p><p class="bulletIndent1">However, blood pressure by itself is not a reliable end point for assessing the adequacy of resuscitation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Normal serum lactate (eg, &lt;2 mmol/L)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Central venous oxygen saturation (ScvO<sub>2</sub>) ≥70 percent, if available and appropriate (invasive monitoring may not be needed in patients who rapidly respond to initial resuscitation); this target is <strong>not</strong> applicable to children with congenital heart disease characterized by mixing lesions</p><p></p><p>Heart rate is an important physiologic indicator of circulatory status that should also be monitored closely. However, many other factors (ie, fever, drugs, anxiety) influence heart rate. Although trends in response to treatment should be carefully monitored, specific target goals for heart rate are difficult to define and may <strong>not</strong> be useful. Children with persistently elevated heart rate unresponsive to repeated fluid boluses should be evaluated for cardiac dysfunction. (See <a class="local">'Red-flag findings'</a> above.)</p><p>Blood lactate can be obtained by bedside testing. Limited evidence suggests that serum lactate that decreases with treatment within two to four hours is associated with better outcomes for children with sepsis. In our practice, our therapeutic target is &lt;2 mmol/L. Small observational studies in children have demonstrated that lactate can correlate with severity of shock and prognosis in sepsis [<a href="#rid10">10-12</a>]. In one observational study of septic shock in children, normalization of lactate (blood lactate &lt;2 mmol/L) within four hours was associated with reduced organ dysfunction, but lactate clearance (reduction ≥10 percent decrease in lactate level) was not [<a href="#rid11">11</a>]. In adults, normalization of lactate and lactate clearance have been associated with decreased mortality. (See  <a class="medical medical_review" href="/d/html/1613.html" rel="external">"Evaluation and management of suspected sepsis and septic shock in adults", section on 'Initial investigations'</a> and  <a class="medical medical_review" href="/d/html/1613.html" rel="external">"Evaluation and management of suspected sepsis and septic shock in adults", section on 'Laboratory'</a>.)</p><p>Except in patients with congenital heart disease with mixing lesions, ScvO<sub>2</sub> &lt;70 percent may also indicate persistence of abnormal end-organ perfusion. However, an ScvO<sub>2</sub> ≥70 percent can be falsely reassuring in sepsis due to hyperdynamic cardiac function, microcirculatory shunting, or mitochondrial dysfunction [<a href="#rid13">13,14</a>]. When measuring ScvO<sub>2</sub> in pediatric patients, pulmonary artery catheters are rarely used. Instead, changes in ScvO<sub>2</sub> are more commonly obtained from a catheter with its tip in the distal superior vena cava [<a href="#rid15">15</a>].</p><p>Identifying physiologic indicators to monitor the effectiveness of resuscitation for children with septic shock is challenging. Noninvasive ultrasonic determination of cardiac index, cardiac output, systemic vascular resistance, and stroke volume is feasible in healthy children, and age-based normative values have been published. Although not widely available, bedside Doppler ultrasound shows promise as a noninvasive method to guide vasoactive therapy by calculating cardiac output and systemic vascular resistance from measurements of blood flow over the pulmonary artery or aorta. (See  <a class="medical medical_review" href="/d/html/6397.html" rel="external">"Shock in children in resource-abundant settings: Initial management", section on 'Clinical and physiologic targets'</a>.)</p><p>Regardless of the method used to measure blood pressure, clinical signs of end-organ perfusion must also be monitored in order to accurately determine the severity of shock and response to treatment. These indicators can be readily monitored noninvasively during the initial management of shock, and (since many children in shock respond well) invasive monitoring can often be avoided. Mean arterial pressure can be measured with a blood pressure cuff. Clinical experience suggests that quality of central and peripheral pulses, skin perfusion, mental status, and urine output are useful signs for assessing response to therapy. Limited observational evidence suggests that capillary refill time may correlate with ScvO<sub>2</sub>. (See  <a class="medical medical_review" href="/d/html/6397.html" rel="external">"Shock in children in resource-abundant settings: Initial management", section on 'Clinical and physiologic targets'</a>.)</p><p>These timelines are proposed as a goal because observational studies suggest that outcomes among children with septic shock are improved when these goals are met. For example, among 1179 children with sepsis across 54 hospitals in New York (United States), completion of a sepsis bundle within one hour was associated with lower risk-adjusted odds ratio (aOR) of in-hospital mortality (0.59, 95% CI 0.38-0.93) [<a href="#rid3">3</a>]. In a single-institution study, bundle-compliant care in 1380 children with septic shock was associated with five times lower mortality (odds ratio [OR] 0.20, 95% CI 0.07-0.53) [<a href="#rid16">16</a>]. In another study, implementation of a sepsis protocol led to a substantial reduction in the proportion of children who no longer had organ dysfunction on day two after presentation (aOR 4.2, 95% CI 1.7-10.4) [<a href="#rid17">17</a>]. However, these timeframes are not always achievable depending upon resources available. Furthermore, individual patients can have good outcomes despite these time limits not being met.</p><p class="headingAnchor" id="H1725409415"><span class="h2">All patients</span><span class="headingEndMark"> — </span>All patients with suspected septic shock should receive continuous monitoring of heart rate, breathing, and pulse oximetry and frequent measurements of blood pressure, timely support of airway and breathing, and rapid fluid resuscitation [<a href="#rid5">5</a>]. Further treatment is determined by the initial response to fluid resuscitation. </p><p class="headingAnchor" id="H19450192"><span class="h3">Airway and breathing</span><span class="headingEndMark"> — </span>Patients with septic shock should initially receive supplemental oxygen to optimize blood oxygen content and, thus, oxygen delivery to tissues if they present with or develop hypoxemia. Oxygenation should be monitored using continuous pulse oximetry.</p><p>Although evidence is lacking in children, we support titration of supplemental oxygen, as needed, to assure oxygen saturation (SpO<sub>2</sub>) 92 to 97 percent and to avoid SpO<sub>2</sub> &gt;97 percent. This approach may prevent the adverse effects (eg, lung injury and microcirculatory vasoconstriction) associated with hyperoxia and free radical generation [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/d/html/6394.html" rel="external">"Continuous oxygen delivery systems for the acute care of infants, children, and adults"</a>.)</p><p>In children who are responding to initial resuscitation without a clear indication for intubation, a trial of noninvasive ventilation such as continuous positive airway pressure ventilation or bilevel positive airway pressure ventilation is suggested, particularly in those with pediatric acute respiratory distress syndrome [<a href="#rid19">19-21</a>]. (See  <a class="medical medical_review" href="/d/html/100358.html" rel="external">"Noninvasive ventilation for acute and impending respiratory failure in children"</a>.)</p><p>Endotracheal intubation using rapid sequence intubation (RSI) is frequently necessary in children with fluid-refractory, catecholamine-resistant septic shock to protect the airway, assist with ventilation, and/or promote oxygenation. In addition, endotracheal intubation and sedation reduce the work of breathing, which may avoid diversion of cardiac output to the muscles of respiration and may improve perfusion to other organs. A rapid overview of RSI in children is provided in the table  (<a class="graphic graphic_table graphicRef51456" href="/d/graphic/51456.html" rel="external">table 3</a>). Emergency endotracheal intubation in children and pediatric RSI are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/6316.html" rel="external">"Technique of emergency endotracheal intubation in children"</a> and  <a class="medical medical_review" href="/d/html/6390.html" rel="external">"Rapid sequence intubation (RSI) in children for emergency medicine: Approach"</a>.)</p><p>When performing RSI in children with septic shock, key actions include [<a href="#rid5">5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with hemodynamic instability should receive appropriate support with fluid and/or catecholamines prior to or during intubation. (See <a class="local">'Fluid resuscitation'</a> below and <a class="local">'Patients with fluid-refractory shock'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pretreatment with <a class="drug drug_pediatric" data-topicid="12875" href="/d/drug information/12875.html" rel="external">atropine</a> is suggested in infants and younger children to counteract reflex bradycardia that may progress to progressive, unstable bradycardia during RSI. (See  <a class="medical medical_review" href="/d/html/6390.html" rel="external">"Rapid sequence intubation (RSI) in children for emergency medicine: Approach", section on 'Pretreatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13398" href="/d/drug information/13398.html" rel="external">Ketamine</a>, if available and <strong>not</strong> contraindicated (eg, patients younger than three months of age or with schizophrenia), is suggested for sedation prior to endotracheal intubation. (See  <a class="medical medical_review" href="/d/html/113029.html" rel="external">"Rapid sequence intubation (RSI) in children for emergency medicine: Medications for sedation and paralysis", section on 'Ketamine'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12907" href="/d/drug information/12907.html" rel="external">Etomidate</a> inhibits cortisol formation and is not recommended unless <a class="drug drug_pediatric" data-topicid="13398" href="/d/drug information/13398.html" rel="external">ketamine</a> is not available or is contraindicated by psychosis. <a class="drug drug_pediatric" data-topicid="13298" href="/d/drug information/13298.html" rel="external">Fentanyl</a> in doses of 1 to 2 mcg/kg given slowly is suggested for infants younger than three months of age.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Short-acting barbiturates and <a class="drug drug_pediatric" data-topicid="12741" href="/d/drug information/12741.html" rel="external">propofol</a> are associated with hypotension and should be <strong>avoided</strong> in children with septic shock.</p><p></p><p>When performing RSI in a child with septic shock, it is important to choose agents that do not worsen cardiovascular status. Previously, <a class="drug drug_pediatric" data-topicid="12907" href="/d/drug information/12907.html" rel="external">etomidate</a> was a common choice because it typically does not compromise hemodynamic stability. However, small observational studies in children with sepsis and septic shock undergoing intubation with or without etomidate indicate that one dose of etomidate is associated with lower levels of serum cortisol, lower cortisol to 11-deoxycortisol ratios, and higher adrenocorticotropic<strong> </strong>hormone levels for up to 24 hours [<a href="#rid22">22,23</a>]. In one case series of 31 children with meningococcal sepsis who required endotracheal intubation, of the eight children who died, seven received etomidate [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H3674437005"><span class="h3">Circulation</span></p><p class="headingAnchor" id="H3991737417"><span class="h4">Establish venous access</span><span class="headingEndMark"> — </span>IV access (preferably two sites and of the largest caliber that can be reliably inserted) should be established within five minutes in patients with septic shock. </p><p>If a peripheral IV cannot be obtained in this time, placement of an IO needle is indicated. (See  <a class="medical medical_review" href="/d/html/6385.html" rel="external">"Vascular (venous) access for pediatric resuscitation and other pediatric emergencies", section on 'Peripheral access'</a> and  <a class="medical medical_review" href="/d/html/6321.html" rel="external">"Intraosseous infusion", section on 'Indications'</a> and  <a class="medical medical_review" href="/d/html/6321.html" rel="external">"Intraosseous infusion", section on 'Drug and fluid administration'</a>.)</p><p class="headingAnchor" id="H71858647"><span class="h4">Obtain laboratory studies</span><span class="headingEndMark"> — </span>Suggested laboratory studies for children with sepsis and septic shock should be obtained as vascular access is achieved and include (see  <a class="medical medical_review" href="/d/html/6395.html" rel="external">"Sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis", section on 'Laboratory studies'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Rapid blood glucose</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Venous or arterial blood gas</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count with differential</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Blood culture</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Blood lactate</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum electrolytes</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Blood urea nitrogen and serum creatinine</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ionized blood calcium</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum total bilirubin</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Alanine aminotransferase (ALT)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prothrombin time (PT)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Partial thromboplastin time (PTT)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>International normalized ratio (INR)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fibrinogen and D-dimer</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urinalysis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urine culture</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other cultures as indicated by clinical findings, lumbar puncture is typically deferred until after emergency resuscitation and administration of empiric antibiotics</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serologic testing as indicated to identify suspected sources of infection</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inflammatory biomarkers (eg, C-reactive protein, procalcitonin) in selected cases (such as children with fever and central lines, community-acquired pneumonia, and infants younger than two months of age) [<a href="#rid24">24-28</a>]. However, some experts draw inflammatory biomarkers in all patients to aid in assessment of adequacy of antimicrobial treatment and source control.</p><p></p><p>The following abnormal laboratory findings are often reported in children with septic shock:</p><p class="bulletIndent1"><span class="glyph">●</span>Lactic acidosis indicated by metabolic acidosis on blood gases and elevation of arterial blood lactate (&gt;2 mmol/L) (see  <a class="medical medical_review" href="/d/html/6395.html" rel="external">"Sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis", section on 'Laboratory studies'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Age-specific leukocytosis or leukopenia  (<a class="graphic graphic_table graphicRef86087" href="/d/graphic/86087.html" rel="external">table 1</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Platelet count &lt;80,000/microL or a decline of 50 percent from highest value recorded over the past three days</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Disseminated intravascular coagulopathy (decreased fibrinogen with increased D-dimer, INR, PT, or PTT) (see  <a class="medical medical_review" href="/d/html/5915.html" rel="external">"Disseminated intravascular coagulation in infants and children", section on 'Diagnosis'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Renal insufficiency suggested by a serum creatinine ≥2 times upper limit of normal for age or twofold increase in baseline creatinine</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Liver dysfunction implied by a total bilirubin ≥4 mg/dL (not applicable to newborn) or ALT &gt;2 times upper limit of normal for age</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pyuria indicating a urinary tract infection</p><p></p><p>Additional discussion of the interpretation of laboratory findings in children with septic shock is provided separately. (See  <a class="medical medical_review" href="/d/html/6395.html" rel="external">"Sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis", section on 'Laboratory studies'</a>.)</p><p class="headingAnchor" id="H197134868"><span class="h5">Treat hypoglycemia</span><span class="headingEndMark"> — </span>Children with septic shock are at risk for hypoglycemia; rapid blood glucose should be measured as IV access is obtained.<strong> </strong>If present, hypoglycemia should be corrected by rapid IV infusion of dextrose as described in the rapid overview  (<a class="graphic graphic_table graphicRef83485" href="/d/graphic/83485.html" rel="external">table 4</a>). </p><p>After initial hypoglycemia is reversed, the clinician should continue to monitor blood glucose. Maintaining a blood glucose &lt;180 mg/dL (8.33 mmol/L) is desirable. Hypoglycemia may also be an indicator of adrenal insufficiency in predisposed children and those with refractory septic shock. (See <a class="local">'Patients at risk for adrenal insufficiency'</a> below and <a class="local">'Patients with catecholamine-resistant shock'</a> below.)</p><p>In normoglycemic young children, a continuous maintenance infusion of dextrose 5 to 10 percent in addition to resuscitation fluids is a reasonable option to prevent the occurrence of hypoglycemia [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H3074988658"><span class="h5">Treat hypocalcemia</span><span class="headingEndMark"> — </span>Children with septic shock are at risk for hypocalcemia [<a href="#rid29">29</a>]; serum ionized calcium should be measured as IV access is obtained. Our practice is to monitor ionized blood calcium levels every one to two hours during initial management of septic shock.</p><p>For patients with a serum ionized calcium &lt;1.1 mmol/L (4.8 mg/dL) and either symptomatic hypocalcemia (eg, positive Chvostek or Trousseau signs, seizures, prolonged QT interval on electrocardiogram, or cardiac arrhythmias) or septic shock who require vasoactive medications, we suggest treatment with IV calcium. The suggested dose is <a class="drug drug_pediatric" data-topicid="12956" href="/d/drug information/12956.html" rel="external">calcium gluconate</a>, 10 percent solution, 50 mg/kg (0.5 mL/kg), maximum dose 2 g (20 mL) by slow IV or IO infusion over five minutes. This suggested dose is equivalent to elemental calcium 5 mg/kg (0.15 mmol/kg), up to 180 mg elemental (4.5 mmol) per single dose [<a href="#rid1">1,2</a>]. </p><p><a class="drug drug_pediatric" data-topicid="12651" href="/d/drug information/12651.html" rel="external">Calcium chloride</a> 10 percent in a dose of 10 to 20 mg/kg (0.1 to 0.2 mL/kg), maximum dose 1 g (10 mL) provides an equivalent dose but should <strong>only</strong> be administered through a central line unless the patient develops impending or actual cardiac arrest.</p><p>Patients receiving a calcium infusion warrant continuous cardiac monitoring. Calcium should be administered in a larger vein or, preferably, a central line. <a class="drug drug_pediatric" data-topicid="12795" href="/d/drug information/12795.html" rel="external">Sodium bicarbonate</a> should <strong>not</strong> be introduced into an IV or IO cannula without flushing before and after administration because of potential precipitation.</p><p>Although definitive evidence to support improved clinical outcomes in humans receiving IV calcium for low ionized calcium levels is lacking [<a href="#rid2">2,30</a>], hypocalcemia is a common finding in critically ill children with sepsis likely due to changes in the hormonal milieu, though the exact pathophysiology remains unclear [<a href="#rid29">29</a>]. Intracellular calcium is necessary for cardiac and smooth muscle contraction. Infants under 12 months of age may rely more heavily on extracellular calcium to maintain adequate cardiac contractility than older patients. Animal models and observational studies have suggested improved physiologic outcomes when hypocalcemia is treated [<a href="#rid31">31,32</a>].</p><p class="headingAnchor" id="H19450206"><span class="h4">Fluid resuscitation</span><span class="headingEndMark"> — </span>For infants and children with septic shock, rapid fluid resuscitation is an essential treatment that should not be delayed. Relative intravascular hypovolemia is common in septic shock (due to vasodilation and capillary leak) and may be severe. The major goal for the initial treatment of septic shock consists of rapid fluid resuscitation to restore tissue perfusion based upon clinical therapeutic endpoints (eg, improvement of quality of pulses, capillary refill time, mental status, urine output) [<a href="#rid5">5,8,9</a>].</p><p>The approach to fluid resuscitation in resource-abundant settings is described in the algorithm and below  (<a class="graphic graphic_algorithm graphicRef128375" href="/d/graphic/128375.html" rel="external">algorithm 1</a>). The approach to fluid resuscitation in extremely preterm infants (&lt;28 weeks gestational age) is discussed separately. (See  <a class="medical medical_review" href="/d/html/126605.html" rel="external">"Neonatal shock: Management"</a> and  <a class="medical medical_review" href="/d/html/126605.html" rel="external">"Neonatal shock: Management", section on 'Fluid resuscitation'</a>.) </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Give initial fluid bolus </strong>– For children with septic shock treated in resource-rich settings (ie, access to acute intensive care capability either locally or via interhospital transport), patients without signs of fluid overload should receive 10 to 20 mL/kg of balanced crystalloid solution such as <a class="drug drug_pediatric" data-topicid="108442" href="/d/drug information/108442.html" rel="external">Lactated Ringer</a>'s solution or multiple electrolyte solution (eg, PlasmaLyte  (<a class="graphic graphic_table graphicRef142468" href="/d/graphic/142468.html" rel="external">table 5</a>)); 0.9% normal <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a> is an acceptable alternative if Lactated Ringer's is not available [<a href="#rid1">1,2</a>]. </p><p></p><p class="bulletIndent1">Fluid volume should be calculated based upon ideal body weight (eg,<sup> </sup>50<sup>th</sup> percentile for age  (<a class="graphic graphic_figure graphicRef63877 graphicRef50006" href="/d/graphic/63877.html" rel="external">figure 1A-B</a> and <a class="graphic graphic_figure graphicRef71721 graphicRef53325" href="/d/graphic/71721.html" rel="external">figure 2A-B</a>)). Infusion of this amount of fluid over 5 to 10 minutes can be achieved with a manual "push-pull" technique or rapid infuser. Use of a time clock has facilitated the timely administration of fluids in at least one setting [<a href="#rid7">7</a>]. However, because very rapid infusion of fluids within under five minutes (such as with use of a rapid infuser) may be harmful in some patients, patients should be continually assessed during and after each fluid bolus. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assess response after initial and subsequent fluid boluses</strong> – After the initial and subsequent bolus infusions, the child should be quickly reassessed for signs of inadequate end-organ perfusion to determine if additional fluid is needed and to identify any signs of fluid overload (eg, pulmonary rales or gallop rhythm). (See <a class="local">'Red-flag findings'</a> above and  <a class="medical medical_review" href="/d/html/6397.html" rel="external">"Shock in children in resource-abundant settings: Initial management", section on 'High-risk conditions'</a>.)</p><p></p><p class="bulletIndent1">Within the first hour of treatment, the physician should determine if the patient is responding to timely fluid administration or not. Patients who are fluid refractory (ie, no improvement or worsening despite crystalloid fluid resuscitation with 40 to 60 mL/kg) warrant vasoactive therapy (eg, continuous infusion of <a class="drug drug_pediatric" data-topicid="13272" href="/d/drug information/13272.html" rel="external">epinephrine</a>  (<a class="graphic graphic_table graphicRef56049" href="/d/graphic/56049.html" rel="external">table 6</a> and <a class="graphic graphic_table graphicRef66791" href="/d/graphic/66791.html" rel="external">table 7</a>) or <a class="drug drug_pediatric" data-topicid="12650" href="/d/drug information/12650.html" rel="external">norepinephrine</a>) tailored to blood pressure. (See <a class="local">'Patients with fluid-refractory shock'</a> below.)</p><p></p><p class="bulletIndent1">In addition, as long as each fluid bolus provides hemodynamic improvement, fluid resuscitation should still continue until tissue perfusion, oxygen delivery, and blood pressure are adequate or signs of fluid overload (rales, gallop rhythm, enlarged liver) develop regardless of the use of vasoactive infusions. Experience suggests that patients with septic shock can require volumes of up to 60 mL/kg in the first hour, and some receive 120 mL/kg or more during the first several hours of fluid administration [<a href="#rid33">33,34</a>]. In children, evidence is lacking to determine if earlier initiation of vasoactive therapy reduces or eliminates the need for large-volume fluid resuscitation and decreases adverse effects increasingly reported with fluid overload. </p><p></p><p class="bulletIndent1">Achievement of targets for timely fluid resuscitation has been associated with reduction in mortality without negative impact on resource utilization [<a href="#rid7">7,16</a>] (see <a class="local">'Outcomes'</a> below). However, despite institution-wide focus on the treatment of septic shock in these studies, the fluid resuscitation goal is not always met, even in these highly-resourced settings. The feasibility of a one-hour target for fluid resuscitation has not been addressed outside of tertiary care pediatric institutions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with signs of fluid overload</strong> – If the patient develops signs of fluid overload (eg, rales, worsening respiratory distress, new or worsening oxygen requirement, gallop rhythm, hepatomegaly, or cardiomegaly or pulmonary edema on chest radiograph), further fluid bolus administration should be omitted or reduced (eg, 5 to 10 mL/kg given over 15 minutes) and continued septic shock treated with vasoactive infusions (See <a class="local">'Indications for vasoactive agents'</a> below.). </p><p></p><p class="bulletIndent1">Patients with signs of fluid overload who continue to receive fluid boluses warrant close monitoring for respiratory and cardiac failure. The clinician should have a low threshold for endotracheal intubation and mechanical ventilation to treat pulmonary edema in these patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Type of fluid</strong> – Evidence suggests that fluid resuscitation in children using balanced crystalloid solution instead of normal <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a> decreases the risk of adverse outcomes. For example, in a multicenter, blinded randomized trial in over 700 children (median age five years) treated for septic shock in India, patients assigned to fluid boluses with a multiple electrolyte solution (MES, PlasmaLyte A  (<a class="graphic graphic_table graphicRef142468" href="/d/graphic/142468.html" rel="external">table 5</a>)) had a lower rate of new or progressive acute kidney injury within the first seven days of treatment compared with those assigned to fluid boluses with normal saline (21 versus 33 percent, respectively; RR 0.6, 95% CI 0.5 to 0.8) [<a href="#rid35">35</a>]. Patients receiving MES were also less likely to develop hyperchloremia during fluid resuscitation. The ICU mortality rate was similar in both groups (about 33 percent). Limitations of this study include the lack of randomization of maintenance fluids administered to the two groups during the study and potential lack of generalizability given the high mortality in both groups relative to prior studies. These findings are consistent with propensity-matched data from a national registry of 7000 children with severe sepsis; exclusive resuscitation with balanced crystalloid fluids for the first 72 hours was associated with a shorter duration of vasoactive infusions, less acute kidney injury, and significantly lower mortality compared with normal saline [<a href="#rid36">36</a>]. However, in a second observational study that used data from insurance records and matched over 2000 children who received balanced crystalloid solution (<a class="drug drug_pediatric" data-topicid="108442" href="/d/drug information/108442.html" rel="external">Lactated Ringer</a>'s) 1:1 with children who received normal saline, mortality, likelihood of acute kidney injury, and length of hospital or intensive care unit stay were similar in both groups [<a href="#rid37">37</a>]. </p><p></p><p class="bulletIndent1">In our practice, we generally use a crystalloid solution instead of <a class="drug drug_pediatric" data-topicid="13277" href="/d/drug information/13277.html" rel="external">albumin solution</a> because of the lack of clear benefit and higher cost of albumin. (See  <a class="medical medical_review" href="/d/html/6397.html" rel="external">"Shock in children in resource-abundant settings: Initial management", section on 'Type of fluid'</a>.)</p><p></p><p class="bulletIndent1">For children with hypoalbuminemia (albumin &lt;3 g/dL), or those who develop a hyperchloremic metabolic acidosis, colloid infusion with albumin 5% is a reasonable option.</p><p></p><p class="bulletIndent1">Although the findings are not consistent and multiple preparations are available, synthetic colloids, such as hydroxyethyl starch solutions, as well as gelatin-derived fluids should be <strong>avoided</strong> because they have been shown to increase the risk of acute kidney injury, coagulopathy, and death in adults with severe sepsis or septic shock, especially administered in volumes &gt;15 mL/kg. (See  <a class="medical medical_review" href="/d/html/6103.html" rel="external">"Treatment of hypovolemia (dehydration) in children in resource-abundant settings", section on 'Crystalloid versus colloid'</a> and  <a class="medical medical_review" href="/d/html/1613.html" rel="external">"Evaluation and management of suspected sepsis and septic shock in adults", section on 'Intravenous fluids (first three hours)'</a>.)</p><p></p><p class="bulletIndent1">Preliminary evidence in one small pediatric trial suggests that administration of hypertonic <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a> may achieve hemodynamic stability with a lower volume of fluid, but its impact on other outcomes relative to normal saline are uncertain [<a href="#rid38">38</a>]; thus, we do <strong>not</strong> advocate use of hypertonic saline outside of an experimental protocol.</p><p></p><p class="headingAnchor" id="H1377200885"><span class="h4">Blood transfusion</span><span class="headingEndMark"> — </span>In hemodynamically unstable children with septic shock (eg, profound hypotension, persistence of lactate &gt;2 mmol/L, progressive/persistent end-organ dysfunction, and/or ScvO<sub>2</sub> &lt;70 percent despite high levels of vasopressor support or profound hypoxia), we suggest blood transfusion to maintain a hemoglobin threshold of 9 g/dL [<a href="#rid1">1,2</a>]. For hemodynamically stable children who are not bleeding, the minimum safe threshold is 7 g/dL. (See  <a class="medical medical_review" href="/d/html/86881.html" rel="external">"Septic shock in children in resource-abundant settings: Ongoing management after resuscitation", section on 'Blood transfusion'</a>.)</p><p class="headingAnchor" id="H1120720011"><span class="h4">Monitoring</span><span class="headingEndMark"> — </span>Once effective circulating volume has been restored, ongoing fluid requirements are guided by monitoring of tissue perfusion, including (see  <a class="medical medical_review" href="/d/html/86881.html" rel="external">"Septic shock in children in resource-abundant settings: Ongoing management after resuscitation", section on 'Ongoing and invasive monitoring'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Mean arterial blood pressure target &gt;5<sup>th</sup> percentile for age</p><p class="bulletIndent1"><span class="glyph">●</span>Capillary refill time</p><p class="bulletIndent1"><span class="glyph">●</span>Urine output</p><p class="bulletIndent1"><span class="glyph">●</span>Replacement of measured or estimated fluid losses</p><p class="bulletIndent1"><span class="glyph">●</span>Serial blood lactate levels</p><p class="bulletIndent1"><span class="glyph">●</span>If available and appropriate, measurement of:</p><p class="bulletIndent2"><span class="glyph">•</span>Arterial blood pressure</p><p class="bulletIndent2"><span class="glyph">•</span>Central venous pressure</p><p class="bulletIndent2"><span class="glyph">•</span>ScvO<sub>2</sub></p><p></p><p>The mean arterial pressure target can be estimated as follows: mean arterial pressure (5<sup>th</sup> percentile at 50<sup>th</sup> height percentile) &gt;1.5 x age in years + 40 [<a href="#rid39">39</a>].</p><p class="headingAnchor" id="H9034264"><span class="h3">Empiric antibiotic therapy</span><span class="headingEndMark"> — </span>Prompt identification and treatment of the site(s) of infection are the primary therapeutic interventions for septic shock, with most other interventions being purely supportive. Blood cultures should be obtained prior to initiating antibiotic therapy as long as they are obtained without delaying antibiotic administration.</p><p class="headingAnchor" id="H2707826900"><span class="h4">Timing</span><span class="headingEndMark"> — </span>For children with septic shock, broad-spectrum IV antibiotic therapy should begin within one hour of presentation, preferably after obtaining appropriate cultures. Effective delivery of antibiotics usually requires two ports or sites for IV access: one devoted to fluid resuscitation and one for antimicrobial delivery. </p><p>Antibiotics should <strong>not</strong> be withheld for children in whom lumbar puncture cannot be performed safely due to hemodynamic instability or coagulopathy  (<a class="graphic graphic_table graphicRef74865" href="/d/graphic/74865.html" rel="external">table 8</a>). If obtaining blood cultures is difficult, it should not impede antibiotic initiation within the first hour. As discussed below, antifungal and antiviral agents should be included as part of the initial regimen for susceptible patients.</p><p>The rationale for the one-hour target for antimicrobial administration comes from observational studies that show poor outcomes with delays in antibiotic therapy, even beyond just one hour. In one pediatric series of 130 patients with severe sepsis or septic shock, delays greater than three hours were associated with significantly increased odds of mortality (OR 4.0 [95% CI 1.3-12.1]) [<a href="#rid40">40</a>]. In another prospective observational study, mortality from septic shock was 1 percent among children who met goals for timely administration of fluids within one hour and antibiotics within three hours versus 4 percent for those who did not (adjusted odds of death 0.2, 95% CI 0.07-0.53) [<a href="#rid16">16</a>]. Each hour delay in antibiotic administration has been associated with an approximately 8 percent increase in mortality in adults. (See  <a class="medical medical_review" href="/d/html/1613.html" rel="external">"Evaluation and management of suspected sepsis and septic shock in adults", section on 'Timing'</a>.)</p><p>Despite institution-wide focus on the treatment of septic shock in these studies, the goal of administering antibiotic therapy within one hour is not always met, even in highly resourced settings. The feasibility of a one-hour target for empiric antibiotic therapy has not been addressed outside of tertiary care pediatric institutions.</p><p>In patients with sepsis-associated organ dysfunction <strong>without</strong> shock, antibiotics should be given as soon as possible but within three hours of implementation of resuscitation protocol/guidelines.</p><p>For patients with suspected sepsis but without clinical shock, an expedited diagnostic evaluation to assess for likely infection or presence of organ dysfunction can reduce unnecessary antibiotic therapy. In one pediatric study, mortality was significantly increased only when antimicrobials were administered &gt;3 hours in comparison to &lt;3 hours, whereas the mortality of patients receiving antimicrobials within &lt;1 hour was not statistically different from those receiving antimicrobials within &lt;3 hours [<a href="#rid40">40</a>]. A second, larger pediatric study demonstrated a significant decrease in mortality if antimicrobials were administered within one hour, but only in the context of a bundle that included a blood culture and fluid bolus [<a href="#rid3">3</a>]. </p><p>Thus, available pediatric studies do not provide a clear time cutoff after which the risk of mortality or other adverse outcomes increases but rather support that there is likely to be an incremental risk for harm as time to antimicrobial initiation increases (in particular, beyond three hours). Thus, while antibiotics should be administered <strong>as soon as possible</strong> after sepsis recognition, it is reasonable to first perform a diagnostic investigation when <strong>clinical signs of shock</strong> are not present, and the diagnosis of sepsis is uncertain. If and when the evaluation supports a likely infection or sepsis (or shock develops during the evaluation), antibiotics should be immediately administered.</p><p class="headingAnchor" id="H2427292477"><span class="h4">Empiric regimens</span><span class="headingEndMark"> — </span>Empiric antibiotics should be broad spectrum and cover all likely pathogens. The choice of antimicrobials can be complex and should consider the child's age, history, comorbidities, clinical syndrome, Gram stain data, and local resistance patterns. Consultation with an expert in pediatric infectious disease is strongly encouraged for all children with septic shock.</p><p>General principles for initial antimicrobial coverage for children who are critically ill with severe sepsis or septic shock include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Maximize the antimicrobial dose by using dosing recommended for severe infection for each administered drug.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antimicrobials that cover against the same organism should not be routinely administered to immunocompetent patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Multidrug therapy is recommended in immunocompromised patients or immunocompetent patients at high risk for multidrug-resistant pathogens.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children with septic shock at risk for methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) due to either high community prevalence or personal/family history of MRSA should receive empiric <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> or an alternative agent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Coverage for enteric organisms should be added whenever clinical features suggest genitourinary and/or gastrointestinal sources (eg, perforated appendicitis or bacterial overgrowth in a child with short gut syndrome).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment for <em>Pseudomonas</em> species should be included for children who are immunosuppressed or at risk for infection with these organisms (ie, neutropenic patient).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Listeria monocytogenes and herpes simplex virus (HSV) are important pathogens in infants ≤28 days of age.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When treating empirically, antibiotics that can be given by rapid IV bolus (eg, beta-lactam agents or cephalosporins) should be administered first, followed by infusions of antibiotics, such as <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a>, which must be delivered more slowly.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ongoing antimicrobial therapy should be modified based upon culture results, including antimicrobial susceptibility and the patient's clinical course.</p><p></p><p>Examples of initial empiric antimicrobial regimens based upon patient age, level of immunocompetence, and previous antibiotic administration include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infants 0 to 28 days of age </strong>(see  <a class="medical medical_review" href="/d/html/5046.html" rel="external">"Management and outcome of sepsis in term and late preterm neonates", section on 'Initial empiric therapy'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12683" href="/d/drug information/12683.html" rel="external">Ampicillin</a> (<a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> in regions with a high prevalence of hospital-acquired MRSA)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>PLUS</strong> <a class="drug drug_pediatric" data-topicid="13134" href="/d/drug information/13134.html" rel="external">ceftazidime</a> or <a class="drug drug_pediatric" data-topicid="13126" href="/d/drug information/13126.html" rel="external">cefepime</a> (<a class="drug drug_pediatric" data-topicid="13129" href="/d/drug information/13129.html" rel="external">cefotaxime</a>, if available); <a class="drug drug_pediatric" data-topicid="12583" href="/d/drug information/12583.html" rel="external">meropenem</a> if there is concern for infection due to a multidrug-resistant gram-negative organism</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>PLUS</strong> <a class="drug drug_pediatric" data-topicid="13332" href="/d/drug information/13332.html" rel="external">gentamicin</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Add <a class="drug drug_pediatric" data-topicid="13247" href="/d/drug information/13247.html" rel="external">acyclovir</a> for suspicion of HSV infection</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children &gt;28 days of age who are normal hosts</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13129" href="/d/drug information/13129.html" rel="external">Cefotaxime</a> <strong>or</strong> <a class="drug drug_pediatric" data-topicid="13136" href="/d/drug information/13136.html" rel="external">ceftriaxone</a>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Add <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> if risk factors for MRSA are present. (See  <a class="medical medical_review" href="/d/html/6065.html" rel="external">"Methicillin-resistant <i>Staphylococcus aureus </i>infections in children: Epidemiology and clinical spectrum", section on 'Epidemiology and risk factors'</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with a possible genitourinary source, add an aminoglycoside (eg, <a class="drug drug_pediatric" data-topicid="13332" href="/d/drug information/13332.html" rel="external">gentamicin</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For possible gastrointestinal source, add <a class="drug drug_general" data-topicid="9775" href="/d/drug information/9775.html" rel="external">piperacillin</a> with tazobactam, <a class="drug drug_pediatric" data-topicid="13167" href="/d/drug information/13167.html" rel="external">clindamycin</a>, or <a class="drug drug_pediatric" data-topicid="12606" href="/d/drug information/12606.html" rel="external">metronidazole</a>. It is best to avoid <a class="drug drug_pediatric" data-topicid="12708" href="/d/drug information/12708.html" rel="external">piperacillin-tazobactam</a> if <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> is being administered because of the risk of renal injury when these two antibiotics are co-administered.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the presence of septic shock in settings with resistant organisms or in at-risk patients, add combination therapy (using at least two antibiotics of different antimicrobial classes) aimed at covering resistant organisms [<a href="#rid9">9,41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children &gt;28 days who are immunosuppressed or at risk for infection with </strong><strong><em>Pseudomonas</em></strong><strong> species</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13126" href="/d/drug information/13126.html" rel="external">Cefepime</a> <strong>or</strong> carbapenem (eg, <a class="drug drug_pediatric" data-topicid="13375" href="/d/drug information/13375.html" rel="external">imipenem</a>, <a class="drug drug_pediatric" data-topicid="12583" href="/d/drug information/12583.html" rel="external">meropenem</a>) in settings where bacterial organisms with extended-spectrum beta-lactamase (ESBL) resistance are prevalent or for patients who have been recently (within two weeks) treated with broad-spectrum antibiotics (eg, third-generation cephalosporin or fluoroquinolone).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Add <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> if risk factors for MRSA are present. (See  <a class="medical medical_review" href="/d/html/6065.html" rel="external">"Methicillin-resistant <i>Staphylococcus aureus </i>infections in children: Epidemiology and clinical spectrum", section on 'Epidemiology and risk factors'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If concerned about resistance to <a class="drug drug_pediatric" data-topicid="13126" href="/d/drug information/13126.html" rel="external">cefepime</a>/<a class="drug drug_pediatric" data-topicid="13134" href="/d/drug information/13134.html" rel="external">ceftazidime</a>/carbapenem, add an aminoglycoside (eg, <a class="drug drug_pediatric" data-topicid="13332" href="/d/drug information/13332.html" rel="external">gentamicin</a>, <a class="drug drug_pediatric" data-topicid="12541" href="/d/drug information/12541.html" rel="external">amikacin</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children who cannot receive penicillin or who have recently received broad-spectrum antibiotics</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12583" href="/d/drug information/12583.html" rel="external">Meropenem</a>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Add <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> if risk factors for MRSA are present. (See  <a class="medical medical_review" href="/d/html/6065.html" rel="external">"Methicillin-resistant <i>Staphylococcus aureus </i>infections in children: Epidemiology and clinical spectrum", section on 'Epidemiology and risk factors'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12949" href="/d/drug information/12949.html" rel="external">Aztreonam</a> <strong>or</strong> <a class="drug drug_pediatric" data-topicid="13157" href="/d/drug information/13157.html" rel="external">ciprofloxacin</a> <strong>PLUS</strong> <a class="drug drug_pediatric" data-topicid="13167" href="/d/drug information/13167.html" rel="external">clindamycin</a> may be used instead of <a class="drug drug_pediatric" data-topicid="12583" href="/d/drug information/12583.html" rel="external">meropenem</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients at increased risk of fungal infection</strong> <strong>(eg, identified fungal source, immunocompromised with persistent fever on broad-spectrum antibiotics)</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Add <a class="drug drug_pediatric" data-topicid="12669" href="/d/drug information/12669.html" rel="external">liposomal amphotericin B</a> or an echinocandin (eg, <a class="drug drug_pediatric" data-topicid="12914" href="/d/drug information/12914.html" rel="external">caspofungin</a>, <a class="drug drug_pediatric" data-topicid="12713" href="/d/drug information/12713.html" rel="external">micafungin</a>) to the antimicrobial regimen [<a href="#rid42">42</a>]. If candidemia is suspected, an echinocandin is the agent of choice.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with risk factors for rickettsial infection</strong> <strong>(eg, travel to or reside in an endemic region)</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Add a <a class="drug drug_pediatric" data-topicid="12830" href="/d/drug information/12830.html" rel="external">tetracycline</a> antibiotic (eg, <a class="drug drug_pediatric" data-topicid="13255" href="/d/drug information/13255.html" rel="external">doxycycline</a>) to the antimicrobial regimen.</p><p></p><p>For neonates with clinical features concerning for HSV infection who may receive <a class="drug drug_pediatric" data-topicid="13247" href="/d/drug information/13247.html" rel="external">acyclovir</a>, viral cultures of vesicles (if present), cerebrospinal fluid and surface (mouth, nasopharynx, eye, and anus can be obtained from one swab ending with the anal swab), and polymerase chain reaction testing (from cerebrospinal fluid and blood) for HSV should be obtained whenever possible. Concerning clinical features include family members with HSV infection, respiratory collapse, elevated transaminases, thrombocytopenia, and/or abnormal cerebrospinal fluid suggestive of HSV infection  (<a class="graphic graphic_table graphicRef66525" href="/d/graphic/66525.html" rel="external">table 9</a>). (See  <a class="medical medical_review" href="/d/html/6037.html" rel="external">"Neonatal herpes simplex virus infection: Clinical features and diagnosis", section on 'Clinical manifestations'</a>.)</p><p class="headingAnchor" id="H2930142152"><span class="h2">Patients at risk for adrenal insufficiency</span><span class="headingEndMark"> — </span>Patients at risk for absolute adrenal insufficiency due to purpura fulminans, recent or chronic treatment with corticosteroids, hypothalamic or pituitary abnormalities, or other causes of congenital or acquired adrenal insufficiency should be treated with stress-dose <a class="drug drug_pediatric" data-topicid="13361" href="/d/drug information/13361.html" rel="external">hydrocortisone</a> early in the course of resuscitation (IV hydrocortisone 50 to 100 mg/m<sup>2</sup>/day or approximately 2 to 4 mg/kg/day, intermittent or continuous infusion, maximum dose 200 mg/day). (See  <a class="medical medical_review" href="/d/html/5825.html" rel="external">"Treatment of adrenal insufficiency in children"</a>.)</p><p>Causes and diagnosis of adrenal insufficiency in children are discussed separately. (See  <a class="medical medical_review" href="/d/html/5828.html" rel="external">"Clinical manifestations and diagnosis of adrenal insufficiency in children"</a> and  <a class="medical medical_review" href="/d/html/5813.html" rel="external">"Causes of primary adrenal insufficiency in children"</a> and  <a class="medical medical_review" href="/d/html/5815.html" rel="external">"Causes of central adrenal insufficiency in children"</a>.)</p><p class="headingAnchor" id="H19450213"><span class="h2">Patients with fluid-refractory shock</span><span class="headingEndMark"> — </span>Vasoactive agents are indicated in patients with fluid-refractory septic shock and are frequently necessary in the initial resuscitation of children with septic shock while hypovolemia is corrected [<a href="#rid5">5</a>]. The choice of agent is determined by whether the blood pressure is normal or hypotensive for age.</p><p class="headingAnchor" id="H3471540227"><span class="h3">Indications for vasoactive agents</span><span class="headingEndMark"> — </span>For patients who continue to have evidence of abnormal perfusion after 40 to 60 mL/kg of crystalloid fluid resuscitation, we suggest initiation of vasoactive therapy (eg, continuous infusion of <a class="drug drug_pediatric" data-topicid="13272" href="/d/drug information/13272.html" rel="external">epinephrine</a>  (<a class="graphic graphic_table graphicRef56049" href="/d/graphic/56049.html" rel="external">table 6</a> and <a class="graphic graphic_table graphicRef66791" href="/d/graphic/66791.html" rel="external">table 7</a>) or <a class="drug drug_pediatric" data-topicid="12650" href="/d/drug information/12650.html" rel="external">norepinephrine</a>)  (<a class="graphic graphic_algorithm graphicRef128375" href="/d/graphic/128375.html" rel="external">algorithm 1</a>). The need for vasoactive medications should be identified and administration begun within the first 60 minutes of resuscitation [<a href="#rid1">1,2</a>]. Although meeting this goal is technically feasible based upon one observational study performed in a tertiary care pediatric institution [<a href="#rid7">7</a>], the feasibility of this goal outside of pediatric tertiary care institutions has not been studied.</p><p>Initial therapy with <a class="drug drug_pediatric" data-topicid="13272" href="/d/drug information/13272.html" rel="external">epinephrine</a> is suggested if myocardial dysfunction is present on cardiac ultrasound or another modality. Otherwise, first-line therapy with either epinephrine or <a class="drug drug_pediatric" data-topicid="12650" href="/d/drug information/12650.html" rel="external">norepinephrine</a> is acceptable. Additional fluid resuscitation may be concurrently administered if physiologic improvement continues to occur following each fluid bolus without signs of fluid overload. (See <a class="local">'Fluid resuscitation'</a> above.)</p><p class="headingAnchor" id="H1223478117"><span class="h4">Central versus peripheral venous access</span><span class="headingEndMark"> — </span>Central venous access is preferred for vasoactive therapy. However, administration of vasoactive medications using a dilute concentration through the most proximal peripheral intravenous (IV) access or an intraosseous (IO) cannula is acceptable during initial resuscitation, while central venous access is being obtained with a low risk of adverse events [<a href="#rid1">1,2</a>]. During peripheral venous administration of vasoactive medications, the access site should be closely monitored for patency. </p><p>Data from observational studies suggest that adverse events are not more frequent when vasoactive therapy is started and temporarily administered through peripheral IV access compared with IO or central access. For example, in a UK study of 198 children with vasoactive drugs administered via a peripheral venous catheter during pediatric critical care transport, 7 of 198 (3.5 percent) experienced adverse events (one extravasation event resulted in tissue necrosis) compared with 9 adverse events among 360 (2.5 percent) with IO or central administration [<a href="#rid43">43</a>]. Observational studies in hospitalized children receiving administration of vasoactive drugs through a peripheral vein indicate that extravasation occurs in approximately 2 percent of patients [<a href="#rid44">44-47</a>]. </p><p>Risk factors for adverse events in children receiving vasoactive therapy through peripheral access include [<a href="#rid43">43-47</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Young age (eg, &lt;one year old)</p><p class="bulletIndent1"><span class="glyph">●</span>Small gauge IV (eg, 24 gauge) </p><p class="bulletIndent1"><span class="glyph">●</span>Hand IV site </p><p class="bulletIndent1"><span class="glyph">●</span>Increased severity of illness</p><p class="bulletIndent1"><span class="glyph">●</span>Longer duration (&gt;three to six hours) of peripheral infusion </p><p class="bulletIndent1"><span class="glyph">●</span>Higher vasoactive medication doses (eg, &gt;10 mcg/kg/min for <a class="drug drug_pediatric" data-topicid="13248" href="/d/drug information/13248.html" rel="external">dopamine</a> or &gt;0.1 mcg/kg/min <a class="drug drug_pediatric" data-topicid="13272" href="/d/drug information/13272.html" rel="external">epinephrine</a>/<a class="drug drug_pediatric" data-topicid="12650" href="/d/drug information/12650.html" rel="external">norepinephrine</a>)</p><p></p><p>For patients initiated on vasoactive infusions without these risk factors, the decision and timing of central venous catheter placement should take into consideration the expected severity and trajectory of illness, as well as other clinical needs that may require secure or central venous access (eg, administration of other caustic medications, high-dose dextrose infusion, continuous sedation, ScvO<sub>2</sub> measurement, or other central blood sampling). If patients without risk factors for peripheral vasoactive complications exhibit low illness severity and are anticipated to wean off vasoactive medications within six hours, placement of a central venous catheter may be avoided. For example, in a retrospective cohort study of over 750 critically ill children receiving vasoactive infusions, of the 231 children who initially received vasoactive therapy (primarily <a class="drug drug_pediatric" data-topicid="13248" href="/d/drug information/13248.html" rel="external">dopamine</a>) by peripheral vein for treatment of shock (93 patients with septic shock), only 54 percent went on to have a central venous catheter placed at a median time of 140 minutes after initiation of vasoactive therapy [<a href="#rid47">47</a>]. Of the same 231 patients with peripheral initiation of vasoactive medications, four (1.7%, 95% CI 0.03-3.4) experienced an extravasation event, all at hand IV sites.</p><p class="headingAnchor" id="H2095968901"><span class="h3">Hypotensive patients</span><span class="headingEndMark"> — </span>For infants with fluid-refractory, hypotensive septic shock, we suggest vasoactive therapy with either an <a class="drug drug_pediatric" data-topicid="13272" href="/d/drug information/13272.html" rel="external">epinephrine</a> infusion or <a class="drug drug_pediatric" data-topicid="12650" href="/d/drug information/12650.html" rel="external">norepinephrine</a> infusion rather than a <a class="drug drug_pediatric" data-topicid="13248" href="/d/drug information/13248.html" rel="external">dopamine</a> infusion  (<a class="graphic graphic_algorithm graphicRef128375" href="/d/graphic/128375.html" rel="external">algorithm 1</a>). The choice between epinephrine and norepinephrine is guided by preference of the clinician, patient physiology, and local system factors [<a href="#rid1">1</a>]. Typically, epinephrine is used in patients with signs of myocardial dysfunction, and norepinephrine is used in patients with signs of low systemic vascular resistance or vasodilation:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13272" href="/d/drug information/13272.html" rel="external">Epinephrine</a> – For an epinephrine infusion, the initial starting dose is 0.05 to 0.1 mcg/kg/minute; titrate to response up to 1.5 mcg/kg/minute [<a href="#rid8">8</a>]. Examples of how to prepare an epinephrine infusion for a 10-kg or 20-kg child are provided in the tables  (<a class="graphic graphic_table graphicRef56049" href="/d/graphic/56049.html" rel="external">table 6</a> and <a class="graphic graphic_table graphicRef66791" href="/d/graphic/66791.html" rel="external">table 7</a>). At doses exceeding 0.1 mcg/kg/minute (and possibly lower in some patients), alpha-adrenergic effects of epinephrine are more pronounced, and systemic vasoconstriction may be more evident. We typically add a second vasopressor if patients have not responded to an epinephrine dose of 1.5 mcg/kg/minute.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12650" href="/d/drug information/12650.html" rel="external">Norepinephrine</a> – For a norepinephrine infusion, the initial dose starting dose is 0.05 to 0.1 mcg/kg/minute; titrate to desired effect up to 2 mcg/kg/minute. Norepinephrine (Levophed) acts on both alpha-1 and beta-1 adrenergic receptors, thus producing potent vasoconstriction as well as a modest increase in cardiac output. This physiologic effect counteracts the toxin-induced vasodilation frequently seen in patients with septic shock. Based upon one small observational study of children with septic shock, norepinephrine therapy is associated with improved cardiac index [<a href="#rid48">48</a>]. However, patients in this study frequently required additional vasoactive agents (eg, <a class="drug drug_pediatric" data-topicid="13272" href="/d/drug information/13272.html" rel="external">epinephrine</a>) to maintain a normal cardiac index.</p><p></p><p>Vasoactive medication may be initially administered through peripheral venous or IO access if central venous access has not been established. However, central venous access should be obtained as soon as practical.</p><p>Further tailoring of the agent and dose can be made according to the type of septic shock as determined by advanced hemodynamic monitoring of the cardiac index and/or systemic vascular resistance. These can be quantified once invasive arterial blood pressure monitoring, ultrasound Doppler of the thoracic aorta, cardiac echocardiography, or ScvO<sub>2</sub> measurement is established [<a href="#rid5">5,49</a>]. (See  <a class="medical medical_review" href="/d/html/86881.html" rel="external">"Septic shock in children in resource-abundant settings: Ongoing management after resuscitation", section on 'Vasoactive drug therapy'</a>.)</p><p>Previous guidelines recommended using bedside clinical signs to categorize septic shock in children as "warm" (presumably indicating high cardiac output and low systemic vascular resistance) or "cold" (presumably indicating low cardiac output and high systemic vascular resistance) [<a href="#rid5">5</a>]. However, the 2020 Surviving Sepsis Campaign pediatric guidelines suggest against using bedside clinical signs in isolation for this purpose and instead recommend use of advanced hemodynamic variables (eg, direct measures of cardiac output/cardiac index, systemic vascular resistance, and ScvO<sub>2</sub>) in addition to physical examination to guide the ongoing resuscitation of children with septic shock or other sepsis-associated organ dysfunction. This change was based on a number of observational studies that demonstrated very poor correlation of bedside clinical signs with more direct measures of myocardial dysfunction, cardiac index, and systemic vascular resistance as measured by advanced monitoring [<a href="#rid2">2,50</a>].</p><p>Both <a class="drug drug_pediatric" data-topicid="13272" href="/d/drug information/13272.html" rel="external">epinephrine</a> and <a class="drug drug_pediatric" data-topicid="12650" href="/d/drug information/12650.html" rel="external">norepinephrine</a> are preferred over <a class="drug drug_pediatric" data-topicid="13248" href="/d/drug information/13248.html" rel="external">dopamine</a> based on the results of two small, randomized controlled trials in children with fluid-refractory septic shock, which demonstrate improved survival with initiation and titration of epinephrine compared with dopamine [<a href="#rid51">51,52</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a single-center, blinded trial of 120 infants and children (1 month to 15 years of age) treated for fluid-refractory septic shock in a pediatric intensive care unit, patients who received infusions of <a class="drug drug_pediatric" data-topicid="13248" href="/d/drug information/13248.html" rel="external">dopamine</a> rather than <a class="drug drug_pediatric" data-topicid="13272" href="/d/drug information/13272.html" rel="external">epinephrine</a> had significantly higher mortality (21 versus 7 percent) and more health care-associated infections (29 versus 2 percent) [<a href="#rid51">51</a>]. In this study the dopamine titration was less potent than the epinephrine titration, which may, in part, explain the differences in outcome. This trial was also stopped early for potential harm.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another single-center, blinded trial of 60 infants and children (3 months to 12 years of age) with fluid-refractory septic shock who received <a class="drug drug_pediatric" data-topicid="13248" href="/d/drug information/13248.html" rel="external">dopamine</a> at doses of 10 to 20 mcg/kg/minute or <a class="drug drug_pediatric" data-topicid="13272" href="/d/drug information/13272.html" rel="external">epinephrine</a> 0.1 to 0.3 mcg/kg/minute, patients who received epinephrine were significantly more likely to have resolution of shock within the first hour than those who received dopamine (12 out of 29 versus 4 out of 31 patients; OR 4.8, 95% CI 1.3-17.2) [<a href="#rid52">52</a>]. Patients who received epinephrine also had significantly better organ function on day three of treatment and more organ failure-free days. Overall, mortality was similar in both groups.</p><p></p><p>Given the small size and limitations of these trials, a larger, multicenter trial that compares equipotent dosing of <a class="drug drug_pediatric" data-topicid="13272" href="/d/drug information/13272.html" rel="external">epinephrine</a> with <a class="drug drug_pediatric" data-topicid="13248" href="/d/drug information/13248.html" rel="external">dopamine</a> is necessary to confirm these findings [<a href="#rid53">53</a>].</p><p>There are no studies assessing <a class="drug drug_pediatric" data-topicid="12650" href="/d/drug information/12650.html" rel="external">norepinephrine</a> in children with septic shock. Randomized trial in adults with septic shock demonstrate lower mortality rate in patients receiving norepinephrine compared with those receiving <a class="drug drug_pediatric" data-topicid="13248" href="/d/drug information/13248.html" rel="external">dopamine</a> and similar mortality compared with those receiving <a class="drug drug_pediatric" data-topicid="13272" href="/d/drug information/13272.html" rel="external">epinephrine</a>. (See  <a class="medical medical_review" href="/d/html/1613.html" rel="external">"Evaluation and management of suspected sepsis and septic shock in adults", section on 'Vasopressors'</a>.)</p><p class="headingAnchor" id="H4128630473"><span class="h3">Normotensive patients</span><span class="headingEndMark"> — </span>Evidence is lacking to provide clear guidance for the management of infants and children with fluid-refractory shock and a normal blood pressure. We suggest that patients with persistent signs of shock but normal blood pressure after initial fluid resuscitation receive low-dose <a class="drug drug_pediatric" data-topicid="13272" href="/d/drug information/13272.html" rel="external">epinephrine</a> infusions (eg, 0.03 to 0.05 mcg/kg/minute). These patients should also continue to receive fluid resuscitation unless signs of volume overload are present. If patients do not respond to fluid resuscitation augmented by low-dose epinephrine infusion, then vasodilatory agents (eg, <a class="drug drug_pediatric" data-topicid="13243" href="/d/drug information/13243.html" rel="external">dobutamine</a> or <a class="drug drug_pediatric" data-topicid="12613" href="/d/drug information/12613.html" rel="external">milrinone</a>) are typically employed. Close monitoring of clinical and laboratory parameters (ie, lactate, urine output, and heart rate) with frequent patient reassessment are necessary to guide the need for escalation of therapies [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H6282460"><span class="h2">Patients with catecholamine-resistant shock</span><span class="headingEndMark"> — </span>Patients with catecholamine-resistant shock warrant evaluation for unrecognized morbidities. Etiologies to evaluate during initial management include pneumothorax, pericardial effusion, intra-abdominal hypertension, ongoing blood loss, and overt adrenal insufficiency (see <a class="local">'Patients at risk for adrenal insufficiency'</a> above). Bedside ultrasound of the lungs, heart, and abdomen by a properly trained and experienced provider may supplement more definitive imaging [<a href="#rid54">54</a>]. (See  <a class="medical medical_review" href="/d/html/86881.html" rel="external">"Septic shock in children in resource-abundant settings: Ongoing management after resuscitation", section on 'Treat reversible etiologies'</a>.)</p><p>We suggest that previously healthy patients who persist with shock in spite of rapid fluid administration and vasoactive infusion receive <a class="drug drug_pediatric" data-topicid="13361" href="/d/drug information/13361.html" rel="external">hydrocortisone</a> in stress doses (50 to 100 mg/m<sup>2</sup>/day or approximately 2 to 4 mg/kg/day, intermittent or continuous infusion, maximum dose 200 mg/day)  (<a class="graphic graphic_table graphicRef61357" href="/d/graphic/61357.html" rel="external">table 10</a>) [<a href="#rid5">5</a>]. Such patients may have relative adrenal insufficiency, more recently termed "critical illness-related corticosteroid insufficiency." However, because definitive evidence of benefit in children is lacking, ongoing management without corticosteroid therapy is a reasonable alternative [<a href="#rid1">1,2</a>].</p><p>Evidence is also lacking regarding the best method to identify adrenal insufficiency in children with refractory septic shock or whether or not it is beneficial to assess adrenal status (either baseline serum cortisol or adrenocorticotropin hormone stimulation testing) prior to corticosteroid administration. Our typical approach is to consider treating with stress-dose <a class="drug drug_pediatric" data-topicid="13361" href="/d/drug information/13361.html" rel="external">hydrocortisone</a> if patients remain in shock despite fluid resuscitation and initial vasoactive medication titration. (See  <a class="medical medical_review" href="/d/html/86881.html" rel="external">"Septic shock in children in resource-abundant settings: Ongoing management after resuscitation", section on 'Adrenal insufficiency'</a>.)</p><p>In patients who require high-dose catecholamines, it is also reasonable to add <a class="drug drug_pediatric" data-topicid="12876" href="/d/drug information/12876.html" rel="external">vasopressin</a>. However, because vasopressin has been associated with increased risk of ischemic events without a clear survival benefit, further titrating catecholamines in children with septic shock who require high-dose catecholamines is a reasonable alternative [<a href="#rid1">1,2</a>]. This decision should be made in consultation with a pediatric critical care specialist whenever possible. (See  <a class="medical medical_review" href="/d/html/86881.html" rel="external">"Septic shock in children in resource-abundant settings: Ongoing management after resuscitation", section on 'Vasoactive drug therapy'</a>.)</p><p class="headingAnchor" id="H10636681"><span class="h1">TRANSFER TO DEFINITIVE CARE</span><span class="headingEndMark"> — </span>After resuscitation, children with septic shock should be managed by clinicians with pediatric critical care expertise in a setting that has the necessary resources to provide pediatric intensive care. Children with septic shock who present to facilities without the necessary clinical expertise or resources should undergo timely transfer to an appropriate facility. Use of a pediatric-specialized team is associated with improved patient survival and fewer adverse effects during transport. Thus, the use of pediatric-specialized teams for transport of children with septic shock is recommended whenever it is available. (See  <a class="medical medical_review" href="/d/html/5796.html" rel="external">"Prehospital pediatrics and emergency medical services (EMS)", section on 'Inter-facility transport'</a>.)</p><p class="headingAnchor" id="H2555418118"><span class="h1">OUTCOMES</span><span class="headingEndMark"> — </span>Increased attention to rapid recognition, timely fluid administration, and early administration of vasoactive agents and antibiotics have been associated with a significant decrease in pediatric mortality from severe sepsis and septic shock [<a href="#rid4">4,5,55-59</a>]. With best clinical practices, mortality from septic shock in resource-rich settings is 0 to 5 percent among previously healthy children and 10 percent in chronically ill children. In one observational study, mortality was 19 percent among children who had persistent shock at pediatric intensive care unit admission, 62 percent of whom did not receive fluid administration and initiation of vasoactive infusions according to guidelines [<a href="#rid60">60</a>]. In another prospective observational study, mortality from septic shock was 1 percent among children who met goals for timely administration of fluids and antibiotics versus 4 percent for those who did not (adjusted odds of death 0.2, 95% CI 0.07-0.53) [<a href="#rid16">16</a>]. </p><p>However, for critically ill children requiring admission to an intensive care unit who develop multiple organ dysfunction syndrome, mortality rates between 10 to 25 percent have been reported [<a href="#rid61">61-63</a>]. Notably, in a single-center study of 321 children treated for septic shock admitted to a pediatric intensive care unit, the administration of rapid IV fluids, antibiotics, and vasoactive infusions within the first hour of shock recognition was associated with a nonsignificant trend toward lower mortality (3.4 versus 6.4 percent) and less new or progressive multiple organ dysfunction syndrome (7.7 versus 12.3 percent) [<a href="#rid17">17</a>]. </p><p class="headingAnchor" id="H1575245890"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/111943.html" rel="external">"Society guideline links: Sepsis in children and adults"</a> and  <a class="medical medical_society_guidelines" href="/d/html/112200.html" rel="external">"Society guideline links: Shock in children"</a>.)</p><p class="headingAnchor" id="H19450291"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topic scope </strong>–<strong> </strong>This topic is intended for the recognition and initial management of children with shock in settings where pediatric intensive care is available and can be reliably performed either locally or via transport. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rapid recognition</strong> – Each pediatric institution should develop and employ a septic shock screening tool  (<a class="graphic graphic_algorithm graphicRef113645" href="/d/graphic/113645.html" rel="external">algorithm 2</a>) to support rapid assessment and resuscitation of children with suspected septic shock. (See <a class="local">'Institutional approach'</a> above.)</p><p></p><p class="bulletIndent1">A clinical diagnosis of severe sepsis or septic shock is made in children who have signs of inadequate tissue perfusion, two or more criteria for the systemic inflammatory response syndrome  (<a class="graphic graphic_table graphicRef86087" href="/d/graphic/86087.html" rel="external">table 1</a>), and suspected or proven infection. (See <a class="local">'Red-flag findings'</a> above and <a class="local">'Signs and symptoms of infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach</strong> – Our approach to initial stabilization and treatment of children with septic shock in settings with access to intensive care is shown in the algorithm  (<a class="graphic graphic_algorithm graphicRef128375" href="/d/graphic/128375.html" rel="external">algorithm 1</a>) and is largely consistent with the 2020 Surviving Sepsis Campaign guidelines. (See <a class="local">'Approach'</a> above and <a class="local">'Institutional guidelines and protocols'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fluid resuscitation</strong> – Children with septic shock and no signs of fluid overload should receive 10 to 20 mL/kg of balanced crystalloid solution (eg, <a class="drug drug_pediatric" data-topicid="108442" href="/d/drug information/108442.html" rel="external">Lactated Ringer</a>'s solution) or normal <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a>. Fluid volume should be calculated based upon ideal body weight (eg, 50<sup>th</sup> percentile for age  (<a class="graphic graphic_figure graphicRef63877 graphicRef50006" href="/d/graphic/63877.html" rel="external">figure 1A-B</a> and <a class="graphic graphic_figure graphicRef71721 graphicRef53325" href="/d/graphic/71721.html" rel="external">figure 2A-B</a>)). We suggest using balanced crystalloid fluids (eg, Lactated Ringer's or multiple electrolyte solutions such as PlasmaLyte  (<a class="graphic graphic_table graphicRef142468" href="/d/graphic/142468.html" rel="external">table 5</a>)) for fluid resuscitation, although 0.9% saline remains an effective alternative (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Infusion of this amount of fluid over 5 to 10 minutes can be achieved with a manual "push-pull" technique or rapid infuser. (See <a class="local">'Fluid resuscitation'</a> above.)</p><p></p><p class="bulletIndent1">For patients who develop signs of fluid overload (eg, rales, worsening respiratory distress, new or worsening oxygen requirement, gallop rhythm, hepatomegaly, or cardiomegaly or pulmonary edema on chest radiograph), omit or reduce the fluid bolus (eg, 5 to 10 mL/kg given over 15 minutes); treat persistent shock with vasoactive infusions. (See <a class="local">'Fluid resuscitation'</a> above.)</p><p></p><p class="bulletIndent1">After the initial infusion, quickly reassess the patient for continued shock and/or signs of fluid overload (eg, pulmonary rales or gallop rhythm). If each fluid bolus provides hemodynamic improvement, then fluid resuscitation should still continue until tissue perfusion, oxygen delivery, and blood pressure are adequate or signs of fluid overload develop. (See <a class="local">'Fluid resuscitation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fluid refractory shock</strong> – For children who continue to have evidence of abnormal perfusion after 40 to 60 mL/kg of crystalloid fluid resuscitation, we suggest initiation of vasoactive therapy (eg, continuous infusion of <a class="drug drug_pediatric" data-topicid="13272" href="/d/drug information/13272.html" rel="external">epinephrine</a>  (<a class="graphic graphic_table graphicRef56049" href="/d/graphic/56049.html" rel="external">table 6</a> and <a class="graphic graphic_table graphicRef66791" href="/d/graphic/66791.html" rel="external">table 7</a>) or <a class="drug drug_pediatric" data-topicid="12650" href="/d/drug information/12650.html" rel="external">norepinephrine</a>). The choice of agent is determined by whether the blood pressure is normal or hypotensive for age  (<a class="graphic graphic_table graphicRef86087" href="/d/graphic/86087.html" rel="external">table 1</a>) (see <a class="local">'Indications for vasoactive agents'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hypotensive shock – For children with fluid-refractory, hypotensive septic shock, we suggest vasoactive therapy with either an <a class="drug drug_pediatric" data-topicid="13272" href="/d/drug information/13272.html" rel="external">epinephrine</a> infusion or <a class="drug drug_pediatric" data-topicid="12650" href="/d/drug information/12650.html" rel="external">norepinephrine</a> infusion rather than a <a class="drug drug_pediatric" data-topicid="13248" href="/d/drug information/13248.html" rel="external">dopamine</a> infusion (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Hypotensive patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Normotensive shock – For children with fluid-refractory, normotensive septic shock, we suggest vasoactive therapy with low-dose <a class="drug drug_pediatric" data-topicid="13272" href="/d/drug information/13272.html" rel="external">epinephrine</a> infusion rather than <a class="drug drug_pediatric" data-topicid="12650" href="/d/drug information/12650.html" rel="external">norepinephrine</a> or <a class="drug drug_pediatric" data-topicid="13248" href="/d/drug information/13248.html" rel="external">dopamine</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Normotensive patients'</a> above.)</p><p></p><p class="bulletIndent1">Central venous access is preferred for vasoactive therapy. However, peripheral intravenous (IV) access or intraosseous (IO) cannula is acceptable during initial resuscitation, while central venous access is being obtained or, in less ill patients, the need for central venous access becomes clear.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Empiric antimicrobial therapy</strong> – Start antimicrobial therapy within the first hour of resuscitation (see <a class="local">'Timing'</a> above). Antifungal and antiviral agents should be included as part of the initial regimen for susceptible patients. (See <a class="local">'Empiric antibiotic therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adrenal insufficiency</strong> – Treat patients at risk for absolute adrenal insufficiency with stress-dose <a class="drug drug_pediatric" data-topicid="13361" href="/d/drug information/13361.html" rel="external">hydrocortisone</a> early in the course of resuscitation. (See <a class="local">'Patients at risk for adrenal insufficiency'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Catecholamine-resistant shock</strong> – Evaluate patients with catecholamine-resistant shock for unrecognized morbidities such as pneumothorax, pericardial effusion, intra-abdominal hypertension, and ongoing blood loss. In addition, for previously healthy patients who persist with catecholamine-resistant shock, we suggest stress-dose corticosteroid therapy  (<a class="graphic graphic_table graphicRef61357" href="/d/graphic/61357.html" rel="external">table 10</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). However, because definitive evidence of benefit in children is lacking, ongoing management without corticosteroid therapy is a reasonable alternative. (See <a class="local">'Patients with catecholamine-resistant shock'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ongoing management</strong> – After initial resuscitation, continue management in a pediatric intensive care unit directed by a pediatric critical care specialist. (See <a class="local">'Transfer to definitive care'</a> above and  <a class="medical medical_review" href="/d/html/86881.html" rel="external">"Septic shock in children in resource-abundant settings: Ongoing management after resuscitation"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Weiss SL, Peters MJ, Alhazzani W, et al. Executive Summary: Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction in Children. Pediatr Crit Care Med 2020; 21:186.</a></li><li><a class="nounderline abstract_t">Weiss SL, Peters MJ, Alhazzani W, et al. Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction in Children. Pediatr Crit Care Med 2020; 21:e52.</a></li><li><a class="nounderline abstract_t">Evans IVR, Phillips GS, Alpern ER, et al. Association Between the New York Sepsis Care Mandate and In-Hospital Mortality for Pediatric Sepsis. JAMA 2018; 320:358.</a></li><li><a class="nounderline abstract_t">Han YY, Carcillo JA, Dragotta MA, et al. Early reversal of pediatric-neonatal septic shock by community physicians is associated with improved outcome. Pediatrics 2003; 112:793.</a></li><li><a class="nounderline abstract_t">Davis AL, Carcillo JA, Aneja RK, et al. American College of Critical Care Medicine Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock. Crit Care Med 2017; 45:1061.</a></li><li><a class="nounderline abstract_t">Cruz AT, Perry AM, Williams EA, et al. Implementation of goal-directed therapy for children with suspected sepsis in the emergency department. Pediatrics 2011; 127:e758.</a></li><li><a class="nounderline abstract_t">Paul R, Melendez E, Stack A, et al. Improving adherence to PALS septic shock guidelines. Pediatrics 2014; 133:e1358.</a></li><li><a class="nounderline abstract_t">Kleinman ME, de Caen AR, Chameides L, et al. Pediatric basic and advanced life support: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations. Pediatrics 2010; 126:e1261.</a></li><li><a class="nounderline abstract_t">Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med 2021; 49:e1063.</a></li><li><a class="nounderline abstract_t">Dugas MA, Proulx F, de Jaeger A, et al. Markers of tissue hypoperfusion in pediatric septic shock. Intensive Care Med 2000; 26:75.</a></li><li><a class="nounderline abstract_t">Scott HF, Brou L, Deakyne SJ, et al. Lactate Clearance and Normalization and Prolonged Organ Dysfunction in Pediatric Sepsis. J Pediatr 2016; 170:149.</a></li><li><a class="nounderline abstract_t">Bai Z, Zhu X, Li M, et al. Effectiveness of predicting in-hospital mortality in critically ill children by assessing blood lactate levels at admission. BMC Pediatr 2014; 14:83.</a></li><li><a class="nounderline abstract_t">Velissaris D, Pierrakos C, Scolletta S, et al. High mixed venous oxygen saturation levels do not exclude fluid responsiveness in critically ill septic patients. Crit Care 2011; 15:R177.</a></li><li><a class="nounderline abstract_t">Fink MP. Bench-to-bedside review: Cytopathic hypoxia. Crit Care 2002; 6:491.</a></li><li><a class="nounderline abstract_t">Dueck MH, Klimek M, Appenrodt S, et al. Trends but not individual values of central venous oxygen saturation agree with mixed venous oxygen saturation during varying hemodynamic conditions. Anesthesiology 2005; 103:249.</a></li><li><a class="nounderline abstract_t">Lane RD, Funai T, Reeder R, Larsen GY. High Reliability Pediatric Septic Shock Quality Improvement Initiative and Decreasing Mortality. Pediatrics 2016; 138.</a></li><li><a class="nounderline abstract_t">Workman JK, Ames SG, Reeder RW, et al. Treatment of Pediatric Septic Shock With the Surviving Sepsis Campaign Guidelines and PICU Patient Outcomes. Pediatr Crit Care Med 2016; 17:e451.</a></li><li><a class="nounderline abstract_t">Asfar P, Calzia E, Huber-Lang M, et al. Hyperoxia during septic shock--Dr. Jekyll or Mr. Hyde? Shock 2012; 37:122.</a></li><li><a class="nounderline abstract_t">Wolfler A, Calderini E, Iannella E, et al. Evolution of Noninvasive Mechanical Ventilation Use: A Cohort Study Among Italian PICUs. Pediatr Crit Care Med 2015; 16:418.</a></li><li><a class="nounderline abstract_t">Dohna-Schwake C, Stehling F, Tschiedel E, et al. Non-invasive ventilation on a pediatric intensive care unit: feasibility, efficacy, and predictors of success. Pediatr Pulmonol 2011; 46:1114.</a></li><li><a class="nounderline abstract_t">Pancera CF, Hayashi M, Fregnani JH, et al. Noninvasive ventilation in immunocompromised pediatric patients: eight years of experience in a pediatric oncology intensive care unit. J Pediatr Hematol Oncol 2008; 30:533.</a></li><li><a class="nounderline abstract_t">den Brinker M, Joosten KF, Liem O, et al. Adrenal insufficiency in meningococcal sepsis: bioavailable cortisol levels and impact of interleukin-6 levels and intubation with etomidate on adrenal function and mortality. J Clin Endocrinol Metab 2005; 90:5110.</a></li><li><a class="nounderline abstract_t">den Brinker M, Hokken-Koelega AC, Hazelzet JA, et al. One single dose of etomidate negatively influences adrenocortical performance for at least 24h in children with meningococcal sepsis. Intensive Care Med 2008; 34:163.</a></li><li><a class="nounderline abstract_t">Damman J, Arias P, Kerner J, et al. Procalcitonin as a Predictive Marker for Bacteremia in Children With a Central Line and Fever. Hosp Pediatr 2019; 9:434.</a></li><li><a class="nounderline abstract_t">Kasem AJ, Bulloch B, Henry M, et al. Procalcitonin as a marker of bacteremia in children with fever and a central venous catheter presenting to the emergency department. Pediatr Emerg Care 2012; 28:1017.</a></li><li><a class="nounderline abstract_t">von Lilienfeld-Toal M, Dietrich MP, Glasmacher A, et al. Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein. Eur J Clin Microbiol Infect Dis 2004; 23:539.</a></li><li><a class="nounderline abstract_t">Kuppermann N, Dayan PS, Levine DA, et al. A Clinical Prediction Rule to Identify Febrile Infants 60 Days and Younger at Low Risk for Serious Bacterial Infections. JAMA Pediatr 2019; 173:342.</a></li><li><a class="nounderline abstract_t">Gomez B, Mintegi S, Bressan S, et al. Validation of the "Step-by-Step" Approach in the Management of Young Febrile Infants. Pediatrics 2016; 138.</a></li><li><a class="nounderline abstract_t">Sanchez GJ, Venkataraman PS, Pryor RW, et al. Hypercalcitoninemia and hypocalcemia in acutely ill children: studies in serum calcium, blood ionized calcium, and calcium-regulating hormones. J Pediatr 1989; 114:952.</a></li><li><a class="nounderline abstract_t">Forsythe RM, Wessel CB, Billiar TR, et al. Parenteral calcium for intensive care unit patients. Cochrane Database Syst Rev 2008; :CD006163.</a></li><li><a class="nounderline abstract_t">Kovacs A, Courtois MR, Barzilai B, et al. Reversal of hypocalcemia and decreased afterload in sepsis. Effect on myocardial systolic and diastolic function. Am J Respir Crit Care Med 1998; 158:1990.</a></li><li><a class="nounderline abstract_t">Porcelli PJ Jr, Oh W. Effects of single dose calcium gluconate infusion in hypocalcemic preterm infants. Am J Perinatol 1995; 12:18.</a></li><li><a class="nounderline abstract_t">Carcillo JA, Davis AL, Zaritsky A. Role of early fluid resuscitation in pediatric septic shock. JAMA 1991; 266:1242.</a></li><li><a class="nounderline abstract_t">Raman S, Peters MJ. Fluid management in the critically ill child. Pediatr Nephrol 2014; 29:23.</a></li><li><a class="nounderline abstract_t">Sankar J, Muralidharan J, Lalitha AV, et al. Multiple Electrolytes Solution Versus Saline as Bolus Fluid for Resuscitation in Pediatric Septic Shock: A Multicenter Randomized Clinical Trial. Crit Care Med 2023; 51:1449.</a></li><li><a class="nounderline abstract_t">Emrath ET, Fortenberry JD, Travers C, et al. Resuscitation With Balanced Fluids Is Associated With Improved Survival in Pediatric Severe Sepsis. Crit Care Med 2017; 45:1177.</a></li><li><a class="nounderline abstract_t">Weiss SL, Keele L, Balamuth F, et al. Crystalloid Fluid Choice and Clinical Outcomes in Pediatric Sepsis: A Matched Retrospective Cohort Study. J Pediatr 2017; 182:304.</a></li><li><a class="nounderline abstract_t">Chopra A, Kumar V, Dutta A. Hypertonic versus normal saline as initial fluid bolus in pediatric septic shock. Indian J Pediatr 2011; 78:833.</a></li><li><a class="nounderline abstract_t">Haque IU, Zaritsky AL. Analysis of the evidence for the lower limit of systolic and mean arterial pressure in children. Pediatr Crit Care Med 2007; 8:138.</a></li><li><a class="nounderline abstract_t">Weiss SL, Fitzgerald JC, Balamuth F, et al. Delayed antimicrobial therapy increases mortality and organ dysfunction duration in pediatric sepsis. Crit Care Med 2014; 42:2409.</a></li><li><a class="nounderline abstract_t">Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med 2017; 45:486.</a></li><li><a class="nounderline abstract_t">Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503.</a></li><li><a class="nounderline abstract_t">Peshimam N, Bruce-Hickman K, Crawford K, et al. Peripheral and Central/Intraosseous Vasoactive Infusions During and After Pediatric Critical Care Transport: Retrospective Cohort Study of Extravasation Injury. Pediatr Crit Care Med 2022; 23:626.</a></li><li><a class="nounderline abstract_t">Owen VS, Rosgen BK, Cherak SJ, et al. Adverse events associated with administration of vasopressor medications through a peripheral intravenous catheter: a systematic review and meta-analysis. Crit Care 2021; 25:146.</a></li><li><a class="nounderline abstract_t">D'Souza M, Pye S, Randle E, et al. Use of peripheral vasoactive drug infusions during the critical care transport of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 infection. Arch Dis Child 2022; 107:e11.</a></li><li><a class="nounderline abstract_t">Turner DA, Kleinman ME. The use of vasoactive agents via peripheral intravenous access during transport of critically III infants and children. Pediatr Emerg Care 2010; 26:563.</a></li><li><a class="nounderline abstract_t">Levy RA, Reiter PD, Spear M, et al. Peripheral Vasoactive Administration in Critically Ill Children With Shock: A Single-Center Retrospective Cohort Study. Pediatr Crit Care Med 2022; 23:618.</a></li><li><a class="nounderline abstract_t">Deep A, Goonasekera CD, Wang Y, Brierley J. Evolution of haemodynamics and outcome of fluid-refractory septic shock in children. Intensive Care Med 2013; 39:1602.</a></li><li class="breakAll">Pediatric Advanced Life Support Provider Manual, Chameides L, Samson RA, Schexnayder SM, Hazinski MF (Eds), American Heart Association, Dallas 2012.</li><li><a class="nounderline abstract_t">Walker SB, Conlon TW, Zhang B, et al. Clinical Signs to Categorize Shock and Target Vasoactive Medications in Warm Versus Cold Pediatric Septic Shock. Pediatr Crit Care Med 2020; 21:1051.</a></li><li><a class="nounderline abstract_t">Ventura AM, Shieh HH, Bousso A, et al. Double-Blind Prospective Randomized Controlled Trial of Dopamine Versus Epinephrine as First-Line Vasoactive Drugs in Pediatric Septic Shock. Crit Care Med 2015; 43:2292.</a></li><li><a class="nounderline abstract_t">Ramaswamy KN, Singhi S, Jayashree M, et al. Double-Blind Randomized Clinical Trial Comparing Dopamine and Epinephrine in Pediatric Fluid-Refractory Hypotensive Septic Shock. Pediatr Crit Care Med 2016; 17:e502.</a></li><li><a class="nounderline abstract_t">Branco RG. Dopamine in Sepsis-Beginning of the End? Pediatr Crit Care Med 2016; 17:1099.</a></li><li><a class="nounderline abstract_t">Ranjit S, Aram G, Kissoon N, et al. Multimodal monitoring for hemodynamic categorization and management of pediatric septic shock: a pilot observational study*. Pediatr Crit Care Med 2014; 15:e17.</a></li><li><a class="nounderline abstract_t">Odetola FO, Gebremariam A, Freed GL. Patient and hospital correlates of clinical outcomes and resource utilization in severe pediatric sepsis. Pediatrics 2007; 119:487.</a></li><li><a class="nounderline abstract_t">Watson RS, Carcillo JA, Linde-Zwirble WT, et al. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med 2003; 167:695.</a></li><li><a class="nounderline abstract_t">Weiss SL, Parker B, Bullock ME, et al. Defining pediatric sepsis by different criteria: discrepancies in populations and implications for clinical practice. Pediatr Crit Care Med 2012; 13:e219.</a></li><li><a class="nounderline abstract_t">Jaramillo-Bustamante JC, Marín-Agudelo A, Fernández-Laverde M, Bareño-Silva J. Epidemiology of sepsis in pediatric intensive care units: first Colombian multicenter study. Pediatr Crit Care Med 2012; 13:501.</a></li><li><a class="nounderline abstract_t">Eisenberg MA, Riggs R, Paul R, et al. Association Between the First-Hour Intravenous Fluid Volume and Mortality in Pediatric Septic Shock. Ann Emerg Med 2022; 80:213.</a></li><li><a class="nounderline abstract_t">Inwald DP, Tasker RC, Peters MJ, et al. Emergency management of children with severe sepsis in the United Kingdom: the results of the Paediatric Intensive Care Society sepsis audit. Arch Dis Child 2009; 94:348.</a></li><li><a class="nounderline abstract_t">Weiss SL, Fitzgerald JC, Pappachan J, et al. Global epidemiology of pediatric severe sepsis: the sepsis prevalence, outcomes, and therapies study. Am J Respir Crit Care Med 2015; 191:1147.</a></li><li><a class="nounderline abstract_t">Schlapbach LJ, Straney L, Alexander J, et al. Mortality related to invasive infections, sepsis, and septic shock in critically ill children in Australia and New Zealand, 2002-13: a multicentre retrospective cohort study. Lancet Infect Dis 2015; 15:46.</a></li><li><a class="nounderline abstract_t">Kutko MC, Calarco MP, Flaherty MB, et al. Mortality rates in pediatric septic shock with and without multiple organ system failure. Pediatr Crit Care Med 2003; 4:333.</a></li></ol></div><div id="topicVersionRevision">Topic 85767 Version 61.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32032264" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Executive Summary: Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32032273" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30043064" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Association Between the New York Sepsis Care Mandate and In-Hospital Mortality for Pediatric Sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14523168" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Early reversal of pediatric-neonatal septic shock by community physicians is associated with improved outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28509730" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : American College of Critical Care Medicine Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21339277" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Implementation of goal-directed therapy for children with suspected sepsis in the emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24709937" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Improving adherence to PALS septic shock guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20956433" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pediatric basic and advanced life support: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34605781" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10663284" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Markers of tissue hypoperfusion in pediatric septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26711848" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Lactate Clearance and Normalization and Prolonged Organ Dysfunction in Pediatric Sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24673817" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effectiveness of predicting in-hospital mortality in critically ill children by assessing blood lactate levels at admission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21791090" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : High mixed venous oxygen saturation levels do not exclude fluid responsiveness in critically ill septic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12493070" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Bench-to-bedside review: Cytopathic hypoxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16052106" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Trends but not individual values of central venous oxygen saturation agree with mixed venous oxygen saturation during varying hemodynamic conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27604184" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : High Reliability Pediatric Septic Shock Quality Improvement Initiative and Decreasing Mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27500722" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Treatment of Pediatric Septic Shock With the Surviving Sepsis Campaign Guidelines and PICU Patient Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22157942" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Hyperoxia during septic shock--Dr. Jekyll or Mr. Hyde?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25828780" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Evolution of Noninvasive Mechanical Ventilation Use: A Cohort Study Among Italian PICUs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21618715" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Non-invasive ventilation on a pediatric intensive care unit: feasibility, efficacy, and predictors of success.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18797201" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Noninvasive ventilation in immunocompromised pediatric patients: eight years of experience in a pediatric oncology intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15985474" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Adrenal insufficiency in meningococcal sepsis: bioavailable cortisol levels and impact of interleukin-6 levels and intubation with etomidate on adrenal function and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17710382" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : One single dose of etomidate negatively influences adrenocortical performance for at least 24h in children with meningococcal sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31097470" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Procalcitonin as a Predictive Marker for Bacteremia in Children With a Central Line and Fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23023470" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Procalcitonin as a marker of bacteremia in children with fever and a central venous catheter presenting to the emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15221617" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30776077" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A Clinical Prediction Rule to Identify Febrile Infants 60 Days and Younger at Low Risk for Serious Bacterial Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27382134" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Validation of the "Step-by-Step" Approach in the Management of Young Febrile Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2723909" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Hypercalcitoninemia and hypocalcemia in acutely ill children: studies in serum calcium, blood ionized calcium, and calcium-regulating hormones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18843706" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Parenteral calcium for intensive care unit patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9847297" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Reversal of hypocalcemia and decreased afterload in sepsis. Effect on myocardial systolic and diastolic function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7710569" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effects of single dose calcium gluconate infusion in hypocalcemic preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1870250" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Role of early fluid resuscitation in pediatric septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23361311" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Fluid management in the critically ill child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37294145" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Multiple Electrolytes Solution Versus Saline as Bolus Fluid for Resuscitation in Pediatric Septic Shock: A Multicenter Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28437373" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Resuscitation With Balanced Fluids Is Associated With Improved Survival in Pediatric Severe Sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28063688" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Crystalloid Fluid Choice and Clinical Outcomes in Pediatric Sepsis: A Matched Retrospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21290201" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Hypertonic versus normal saline as initial fluid bolus in pediatric septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17273118" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Analysis of the evidence for the lower limit of systolic and mean arterial pressure in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25148597" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Delayed antimicrobial therapy increases mortality and organ dysfunction duration in pediatric sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28098591" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19191635" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35481954" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Peripheral and Central/Intraosseous Vasoactive Infusions During and After Pediatric Critical Care Transport: Retrospective Cohort Study of Extravasation Injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33863361" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Adverse events associated with administration of vasopressor medications through a peripheral intravenous catheter: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34656981" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Use of peripheral vasoactive drug infusions during the critical care transport of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20657339" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The use of vasoactive agents via peripheral intravenous access during transport of critically III infants and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35446810" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Peripheral Vasoactive Administration in Critically Ill Children With Shock: A Single-Center Retrospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23812341" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Evolution of haemodynamics and outcome of fluid-refractory septic shock in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23812341" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Evolution of haemodynamics and outcome of fluid-refractory septic shock in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32740190" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Clinical Signs to Categorize Shock and Target Vasoactive Medications in Warm Versus Cold Pediatric Septic Shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26323041" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Double-Blind Prospective Randomized Controlled Trial of Dopamine Versus Epinephrine as First-Line Vasoactive Drugs in Pediatric Septic Shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27673385" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Double-Blind Randomized Clinical Trial Comparing Dopamine and Epinephrine in Pediatric Fluid-Refractory Hypotensive Septic Shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27814334" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Dopamine in Sepsis-Beginning of the End?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24196006" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Multimodal monitoring for hemodynamic categorization and management of pediatric septic shock: a pilot observational study*.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17332201" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Patient and hospital correlates of clinical outcomes and resource utilization in severe pediatric sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12433670" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The epidemiology of severe sepsis in children in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22460773" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Defining pediatric sepsis by different criteria: discrepancies in populations and implications for clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22460772" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Epidemiology of sepsis in pediatric intensive care units: first Colombian multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35641356" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Association Between the First-Hour Intravenous Fluid Volume and Mortality in Pediatric Septic Shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19131419" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Emergency management of children with severe sepsis in the United Kingdom: the results of the Paediatric Intensive Care Society sepsis audit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25734408" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Global epidemiology of pediatric severe sepsis: the sepsis prevalence, outcomes, and therapies study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25471555" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Mortality related to invasive infections, sepsis, and septic shock in critically ill children in Australia and New Zealand, 2002-13: a multicentre retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12831416" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Mortality rates in pediatric septic shock with and without multiple organ system failure.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
